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Abstract
Drug Design, Biological Activity, and Metabolic Consequences of Cytotoxic
Platinum Compounds: Utilizing Fluorescent Tagging to Understand Drug Action
and Metabolism
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University
By
Brad T. Benedetti
Director: Dr. Nicholas P. Farrell
Professor
Department of Chemistry, Virginia Commonwealth University
April, 2011

Platinum drugs are among the most commonly used chemotherapeutics for the
treatment of testicular, head and neck, ovarian, small cell lung, and colorectal
carcinomas.

Although the current set of platinum chemotherapeutics has proven

somewhat successful, the overall success of platinum based drugs is limited due to
acquired drug resistance and a limited range of tumor types that are treatable with the
current regime. The development of novel cytotoxic platinum based compounds, both
trans- and polynuclear, provides for the promising treatment of clinical platinum drug
resistant tumors. While the cytotoxic activity of platinum drugs provides for a hopeful
outlook, the ultimate factors that affect the success of chemotherapeutics are the fine
balance between cytotoxic activity and metabolic deactivation.
In general, this work reports the drug design/drug action, and pharmacokinetic
consequences of anticancer compounds aimed to fight mechanisms of cisplatin
resistance. In the first project, we report the biological and biophysical studies aimed at

xv

understanding

and

improving

upon

the

pharmacokinetic

properties

of

chemotherapeutics; specifically, understanding their interactions with serum proteins.
This work resulted in the discovery of using carboxylate ligands to modulate the
reactivity of trans-platinum based compounds towards sulfur containing proteins with
consequent effects on drug efficacy. In addition, we report an in depth look into the
biological consequences of non-covalent platinum drug-protein interactions on drug
efficacy, and introduce the use of novel Platinum-NBD fluorescent conjugates as probes
for drug metabolism. In the second project we report the design, synthesis, and
biological consequences of fluorescent drug derivatives based on the NBD fluorophore,
for use in understanding drug action and drug metabolism. As a result of this fluorescent
drug labeling, TriplatinNC, a non-covalent platinum based chemotherapeutic, was found
to specifically target nucleolar DNA/RNA, due to its high charge, and inhibit ribosomal
RNA production in cancer cells. The use of fluorescent derivatization also resulted in
the development of a series of novel water-soluble trans-platinum complexes, with
greater cytotoxicity than cisplatin. Therefore, these data resulted in the understanding
of, and improvement upon the pharmacokinetic profile of platinum chemotherapeutics,
as well as the development of novel fluorescent platinum conjugates with novel
metabolic and cytotoxic profiles.

1

Chapter 1: Cancer and Platinum Based Chemotherapeutics

1.1 Cancer
Despite an enormous amount of research being committed to the treatment of cancer
over the last few decades, cancer still remains a worldwide killer. Deaths from cancer
account for 23% of the total deaths in the United States, second only to heart disease. 1
While the number of deaths resulting from heart disease have been drastically reducing
over the years, the total number of deaths from cancer remains constant. Cancer is
described as a class of diseases in which a group of cells display uncontrolled growth
and invasion that intrudes upon and destroys adjacent tissues. To date, there are
multiple treatments available to fight the spread of cancer, including, surgery,
chemotherapy, immunotherapy, and radiation therapy.2 Among the most commonly
used chemotherapeutics for the prevention and treatment of cancer are Taxol, Cisplatin,
Carboplatin, 5-FU and Doxorubicin.3

1.2 Cisplatin and Platinum Analogs
Cisplatin, c-DDP, cis-PtCl2(NH3)2 was first synthesized by Michel Peyrone in 18454, but
remained relatively unnoticed until the early 1960‟s when Barnett Rosenberg, a
professor of biophysics and chemistry at Michigan State University, began to investigate
the effect of electrical currents on bacterial cell growth.5 (Figure 1.1) He discovered
that after treatment with electrical current from "inert" platinum electrodes E. coli were
produced that were 300 times their normal length. This treatment had successfully
prevented cell division, but not other growth processes and ultimately led to the

2
elongation. Eventually, it was determined that the electric field applied to the E. Coli was
not the cause of the elongation and that it was in fact the production of a platinum
complex formed during reaction between the platinum electrodes and components of
the media containing the bacteria. This platinum complex was eventually determined to
be cis-PtCl2(NH3)2, cisplatin. The serendipitous discovery of cisplatin changed the face
of anti-tumour treatment of the 1970‟s.6 Cisplatin was eventually found to be highly
effective against multiple tumor lines and entered into clinical trials in 1971 and was
licensed solely to Bristol-Myers Squibb in 1977.7
The cytotoxicity of cisplatin is accepted to result mainly from the formation of
bifunctional 1,2-intrastrand DNA crosslinks with purine bases, resulting in the inhibition
of DNA synthesis and replication.8 The most notable crosslinks seen are the 1-2intrastrand G-G adducts which form nearly 90% of the adducts. Also possible is the
formation of 1-2-interstrand adducts, but to a much lesser extent. (Figure 1.2) The DNAreactive platinum species are considered to be monoaquo and diaquo complexes – in
general [Pt(amine)2(H2O)2]2+ or [Pt(amine)2(Cl)(H2O)]+ -

produced upon hydrolysis of

the administered drugs, and the chemistry of these species has been well examined. 9
Following Cisplatin-DNA binding, the subsequent adduct is recognized by a high
mobility group (HMG)-domain protein, which binds tightly to the Cisplatin-DNA
complex.10-11 This adduct formation causes de-stacking of the nucleotide bases,
resulting in the DNA helix becoming kinked. Therefore it is postulated that this
interaction could potentially provide a “shielding” effect from typical DNA repair protein
pathways.12 This inhibition of traditional DNA repair pathways results in the induction

3
cell signaling pathways, generally, p53, Bcl-2, caspases, and MAPK pathways,
eventually leading to an apoptotic response.13
With the success of platinum based chemotherapy following the introduction of
cisplatin in to the clinics in 1978, the development of subsequent platinum regimes has
spiked tremendously. Although this large amount of research has resulted in many
promising compounds, only two subsequent platinum drugs, carboplatin and oxaliplatin,
have been successfully approved for anti-cancer use by the FDA.7 (Figure 1.1)
Carboplatin, invented by Rosenberg and his colleagues, was developed primarily to
decrease the toxic side effects associated with cisplatin treatment, and is currently the
only other platinum chemotherapeutic effective against a wide range of tumor types.14-15
The addition of the bidentate cyclobutanedicarboxylate leaving group is more stable
than the chloride groups of cisplatin, therefore slowing down the reactivity in the
bloodstream and allowing more drug to reach the tumor intact.14 Oxaliplatin, the most
recent platinum compound to be introduced to the clinics, was approved in across
Europe in 1996 and in the United States in 2000 for use against advanced colorectal
carcinoma.14,16

To date, Oxaliplatin is the only platinum chemotherapeutic to be

approved for use against colorectal tumors.16
Following the development of cisplatin and initial studies on the general structure
activity relationship of subsequent compounds, a set of rules was established to aid in
the discovery of new platinum chemotherapeutics.17 These rules state that the
compound(s) should have (1) two ammine groups in the cis geometry (2) two leaving
groups also in the cis geometry (3) leaving groups which are only moderately easy to
remove and (4) neutral charge.18 All current clinical platinum chemotherapeutics have

4
followed these rules. Unfortunately the success of platinum based chemotherapeutics
is limited due to eventual acquired drug resistance and a limited range of tumor types
that are treatable with the current regime. Therefore, the current research motivation is
to find new platinum based drugs which exert a uniquely distinct mode of DNA binding,
which could overcome clinical resistance to the currently used platinum drugs.

5

Figure 1.1 Chemical Structures of Clinical Platinum-Based Chemotherapeutics:
Cisplatin (top left), Carboplatin (top right), and Oxaliplatin (bottom)

6

Figure 1.2 DNA adducts formed after treatment of Cisplatin

7
1.3 Trans-Platinum Compounds
One common feature among current clinical platinum therapeutics is the bis, cis
orientation of the labile leaving groups. The trans isomer of cisplatin, trans-[PtCl2(NH3)2]
is much less toxic than the cis counterparts, presumably due to its inability to form 1,2intrastrand cross links between the N7 atoms of adjacent guanines in double strand
DNA.19-20 Although transplatin itself is clinically inactive, substitution of one of the NH 3
groups with a planar heterocyclic ligand such as pyridine, thiazole, quinoline,
isoquinoline, etc., yields a class of active transplanaramine platinum chemotherapeutics
(TPA‟s).(Figure

1.3)

These TPA

compounds

possess

substantially enhanced

cytotoxicity profiles as compared to the “parent” trans-[PtCl2(NH3)2], with IC50 values in
the 1-10µM range across numerous tumor cell lines.21

Most interestingly, TPA

compounds usually exhibit no cross resistance with cisplatin or oxaliplatin and thus
demonstrate a unique cytotoxicity profile across the NCI tumor panel.22 The use of
other carrier ligands such as iminoethers, heterocyclic aliphatic amines, and aliphatic
amines, has also been used to produce a wide range of trans-platinum compounds with
potential chemotherapeutic application.23-24 The use of carboxylates as leaving groups
for TPA‟s has also been used, first introduced to address the low aqueous solubility of
TPA‟s.25 These carboxylate derivatives have shown similar cytotoxicities to their parent
chlorides.26-27 The use of carboxylate ligands also results in increased cellular
accumulation even in cisplatin and oxaliplatin-resistant cell lines.26-27 In attempts to
optimize drug design, previous studies in our group have shown that the use of formate
as leaving group gives enhanced cytotoxicity in comparison to acetate. 28

8

29

Figure 1.3 Chemical structures of selected Trans-Platinum based anticancer compounds.

9
1.4 Polynuclear Platinum Compounds
Polynuclear platinum compounds represent a distinct class of anticancer drugs,
whose structural and biological effects differ drastically from the classical mononuclear
platinum family of compounds, (cisplatin, carboplatin, etc.).12,30 The first clinical
compound resulting from this research, BBR3464, is a tri-nuclear, bi-functional DNA
binding agent with an overall charge of 4+. (Figure 1.4)

BBR3464, the only non-

cisplatin-like molecule to enter human clinical trials, and has promising activity in
cisplatin-resistant, cisplatin-sensitive and p53 mutant tumors.31-33 BBR3464 is also forty
to eighty fold more potent on a molar basis than cisplatin. 34 BBR3464 is capable of
forming long range DNA adducts, including 1,4 and 1,6 inter-strand crosslinks. (Figure
1.5)

The nature of these long-range adducts provides the basis for the enhanced

cytotoxic nature of the compound and also for the ability BBR3464 to effectively treat
cisplatin resistant tumors.35-36

1.5 Non-Covalent Polynuclear Platinum Compounds
Most platinum chemotherapeutics bind to DNA in a covalent manner by
formation of a Pt-DNA adduct. Replacement of the chloride leaving groups of BBR3464
with substitutionally „inert‟ ammine ligands or „dangling‟ ammines, H2N(CH2)6NH3+, gives
„non-covalent‟ polynuclear platinum compounds; most notably TriplatinNC. (Figure 1.4)
TriplatinNC is a highly positively charged, (+8) non-covalent derivative of the phase II
clinical platinum drug, BBR3464.37 The crystal and molecular structure of TriplatinNC
associated with a double-stranded B-DNA dodecamer 5′-d(CGCGAATTCGCG)2 at 1.2
Å resolution (PDB:2DYW), shows formation of phosphate clamps, involving two modes

10
of DNA binding: "backbone-tracking", by following along the phosphate backbone of one
strand, or "groove-spanning", by crossing over the minor groove to interact with both
strands.38 (Figure 1.6) The phosphate clamp motif is a discrete third mode of DNA
binding, distinct from intercalation or minor groove binding. These interactions are
mediated through hydrogen bonding, and are analogous to the "arginine fork”, an
important motif for protein-DNA interactions, where positively charged guanidino groups
of arginine, interact with negatively charged oxygens of DNA phosphate.39-41 TriplatinNC
has significantly higher cellular accumulation than either BBR3464 or cisplatin, and in
some cases equivalent or greater cytotoxicity than cisplatin.42-43

11

Figure 1.4 Chemical Structures Selected Covalent and Non-Covalent DNA Binding Platinum Drugs

12

Figure 1.5 Long-Range DNA-Adducts formed by BBR3464

13

Figure 1.6 Crystal Structure of TriplatinNC Interactions with DNA

44
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1.6 Pharmacological Factors Affecting Platinum Based Treatments
There are four main factors which control the pharmacokinetics of compounds in
biological systems. These factors include but are not limited to, absorption, distribution,
metabolism, and elimination. These four criteria greatly affect the bioavailability and
kinetics of drug exposure towards the biological system of interest.
Absorption refers to the ability of a drug, following administration, to effectively
reach the systemic circulation; either by passing through intestinal cell membranes in
the case of orally administered compounds or other natural membranes such as the
blood brain barrier.45 Once in systemic circulation, the process of metabolism begins to
decompose the compounds of interest into drug metabolites. If the metabolites of the
compound are „inert‟ after metabolism, a large portion of the pharmacological effect is
thus diminished and the drug administered can no longer be distributed to the site of
action. Metabolism can occur by reactions with liver redox enzymes such as
cytochrome P450 and through interactions with proteins in the blood stream. 46
Prolonged elimination half-lives can result in reduced tolerability of the administered
drug in patients, often warranting removal of compounds of interest from clinical trials.
About 75% of drug candidates do not enter clinical trials due to pharmacokinetics
problems in pre-clinical studies. Also, about 40% of molecules that fail in clinical trials
do so because of pharmacokinetics problems.46
In addition to the pharmacokinetic properties that affect all administered drugs,
the three major pharmacological factors affecting the success of any type of platinumbased cancer therapy are cellular uptake, the frequency and the type of DNA adducts
formed and metabolic deactivation. Metabolic deactivation is mediated through
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interactions of the small molecules with biomolecules, specifically sulfur-containing
amino acids in proteins, and these interactions may contribute to the toxic side effects
associated with platinum based treatments.47-48 From a solely chemical standpoint,
these metals, following aquation, would be expected to act as soft Lewis acids and to
form stable complexes with S or N donors found in proteins.49 Thus, the rate of
hydrolysis of the leaving ligand greatly affects the amount of protein binding.
One of the most plausible extracellular non-DNA targets for platinum compounds
is blood serum. Serum is the liquid portion of blood, approximately 55% of the total
volume, excluding red and white blood cells, containing all plasma proteins at a
concentration of 70 g/L.50 These proteins include fibrinogen, globulins, and human
serum albumin (HSA). Albumin, the most abundant plasma protein and the most likely
candidate for drug metabolic interactions, is a 585 amino acid, 66 kDa, single chain
protein involved in transportation of numerous drugs and ligands.51-52 HSA is largely αhelical and contains 17 disulfide bridges and only one free cysteine, Cys-34.

This

residue, along with Met-298 is speculated as the primary binding sites of cisplatin.53 It is
mainly accepted, in the case of most Pt-compounds, that once coordinated to S or N
donors in plasma proteins or other biomolecules, platinum compounds are effectively
„deactivated‟ and eliminated from the body; thus never reaching their desired site of
action.48 Severe nephrotoxicity has also been associated with interactions of platinum
anti-tumor compounds with thiol groups of proteins.54
Plasma proteins in the systemic circulation are not the only „deactivator‟ or
scavenger of platinum chemotherapeutics. Once removed from the systemic circulation
and inside the cellular target there are a large number of molecules, in a high enough
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concentration, to interact with the platinum moiety.55 Among these biomolecules of
interest is the tri-peptide glutathione (GSH). Glutathione has been chosen due to its role
as a determinant of cellular sensitivity to a wide variety of drugs and cytotoxic agents.
The normal intracellular concentration of GSH ranges from 5 to 10 mM

56

, therefore the

binding of platinum-containing drugs to GSH is highly probable. Studies of interactions
between GSH and c-DDP/transplatin showed the formation of a 1:1 Pt-GSH species in
the case of the trans- isomer, and eventual liberation of the NH3 ligand to form a 1:2 PtGSH species in the case of c-DDP.57-58 Also, clinical and preclinical studies of cellular
systems with elevated levels of GSH have show to be more resistant, in varying
degrees, to c-DDP.59 Studies with polynuclear platinum compounds have similarly
shown the formation of Pt-GSH species in varying ratios, but ultimately, the interactions
of these platinum compounds may be expected to follow that of cisplatin and its
mononuclear analogues.60-61 Ultimately, therapeutic efficiency will be reflected as a
balance between metabolic deactivating interactions and biological consequences of
DNA toxicity.
In an effort to improve the therapeutic efficiency, by minimizing interactions with
plasma proteins, novel formulations of platinum compounds have been developed.62
One pathway to minimize metabolic interactions can be through replacement of the
most commonly used –Cl leaving group with other, more stable ligands.

Cell

Therapeutics Inc. (CTI) is currently evaluating a derivative of the polynuclear platinum
compound BBR3610 and has shown that replacement of the –Cl ligand with a
carboxylate, such as butyrate or capronate, results in much lower plasma binding in
vitro, while still retaining its cytotoxicity profile in vivo.63 This „carboxylate‟ strategy has
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also been employed to improve the pharmacokinetic properties of mono-nuclear transplatinum compounds.25 In these trans-platinum compounds, carboxylate groups were
added at first to simply enhance aqueous solubility, but have also been shown to
decrease the rate of hydrolysis, therefore possibly allowing for decreased metabolic
deactivation.

1.8 Fluorescence Cellular Imaging of Platinum Compounds
The use of molecular imaging techniques, such as fluorescence confocal
microscopy, is an important tool in the understanding of platinum drug trafficking and
intracellular distribution. Primarily, it is necessary to understand the ability of each
compound to effectively penetrate the cell be delivered to the desired site of interest, in
most cases, nuclear DNA.

Moreover, information regarding the subcellular

compartments, transporters, and receptors with which these drugs localize can provide
vital information explaining metabolic deactivation, resistance mechanisms, and toxicity.
Hambley has summarized recent fluorescent approaches to monitoring platinum
trafficking.64 Previous attempts at “tagging” platinum compounds have yielded cisplatin
derivatives in which FITC and Alexa based fluorophores have been utilized. These
derivatives tend to mimic the biological properties of the fluorescent “tag” rather than the
platinum moiety itself.64 A number of platinum complexes incorporating fluorescent
probes have been developed not just to monitor the localization of cisplatin, but rather
as a class of potentially chemotherapeutic platinum drugs in their own right with the aim
of combining the benefits of intercalating agents with those of platinum complexes. 65-66
The main objective to successfully create fluorescently labeled compounds that truly

18
mimic the biological properties of the parent compound is to minimize the size of the
fluorescent probe and retain the original structure and solubility properties after
conjugation.

1.7 Concluding Remarks and Project Overview
Despite an enormous amount of research being committed to the treatment of
cancer over the last few decades, cancer still remains a worldwide killer. Although the
current set of platinum chemotherapeutics has proven somewhat successful, the overall
success of platinum based chemotherapeutics is limited due to eventual acquired drug
resistance and a limited range of tumor types that are treatable with the current regime.
The development of novel cytotoxic platinum based compounds, trans- and polynuclear,
provides for promising treatment of clinical “platin” drug resistant tumors. While the
cytotoxicity activity of many platinum drugs provides for a hopeful outlook, the ultimate
factors affecting the success of chemotherapeutics are the fine balance between
cytotoxic activity and metabolic deactivation.

By finding this balance,

it may be

possible to defer many of the toxic side effects associated with chemotherapeutics, and
thus provide for substantial increases in mean tolerated dosages, thus, facilitating the
better development of platinum compounds for the treatment and prevention of cancer.
The long term objective of this thesis was to evaluate, understand, and improve
the pharmacokinetic profile of platinum chemotherapeutics through the use of standard
biological and chemical protocols and through the development of novel fluorescent
imaging assays.

Chapter 1 of this thesis presents an overview of platinum
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chemotherapeutics and the role of metabolism in the overall activity of these
compounds.
Chapter 2 presents a series of cytotoxic trans-platinum compounds, in which we
evaluate the ability of using carboxylate ligands to modulate the reactivity of the
compounds towards sulfur containing proteins and consequently the biological effect on
drug efficacy. The work in this chapter has been completed and is in submission to
Dalton Transactions.
In Chapter 3, the interactions of various polynuclear platinum complexes with
mouse plasma, human plasma, and human serum albumin were studied. The
implications for protein pre-association and plasma stability of polynuclear platinum
compounds, both covalent and non-covalent are discussed.
Chapter 4 builds on the biophysical studies observed in Chapter 3 and takes and
in depth look into the biological consequences of non-covalent platinum drug-protein
interactions on drug efficacy. This chapter also introduces the use of novel PlatinumNBD fluorescent conjugates as probes for drug metabolism. This work has been
completed and is in submission to Molecular Pharmaceutics.
Chapter 5 reports the anticancer activity and primary insights into the mechanism
of action of a series of novel water-soluble trans-platinum complexes that incorporate an
amino ligand composed of an aliphatic carbon chain and a planar fluorophore
intercalator, NBD. This work has been completed and is in submission to JACS.
Appendix 1 is a completed manuscript, in submission to PNAS, which discusses
the biological consequences and mechanism of action of TriplatinNC, based on the
fluorescent tagging of this compound with the NBD fluorophore.

Appendix 2 is also a
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completed manuscript, published in Dalton Transactions, which focuses on the
biophysical aspects of the pre-association of polynuclear platinum anticancer agents on
a protein, human serum albumin and the implications for drug design.
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Abstract
Transplatinum planaramine (TPA) compounds which possess carboxylate
ligands in the trans position have been shown to be potential antitumor drugs in a
variety of cell types, including cisplatin and oxaliplatin resistance cell lines. 1-3 In this
work, we ask whether the nature and stability of the carboxylate ligand can be tuned in
an attempt to manipulate the extent of serum protein binding; and consequently
influence cytotoxicity, cellular drug accumulation and DNA adduct formation. Monitoring
the interactions of selected TPA‟s with N-Acetyl Methionine (NAM) by 1H and 195Pt NMR
show large differences in rate of sulfur binding. TPA containing acetate ligands show a
much lower sulfur binding rate than those possessing formate leaving groups. The
same trend was seen after acetate and formate TPA compounds were incubated with
human serum albumin and the reaction was monitored for 24hrs. To understand
whether in vitro results could be translated in vivo, MTT cytotoxicity assays were
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conducted for each compound, before and after incubation with whole serum. Both the
formate and acetate compounds, t-Pt(4-pic)NH3(OFm)2 and t-Pt(4-pic)NH3(OAc)2,
showed minimal losses in cytotoxic efficacy and outperformed cisplatin after preincubation with serum. The same trends were seen when monitoring the effects of
protein binding on cellular uptake and DNA platination. The rate of protein binding/drug
deactivation was shown to be directly related to the stability of the leaving group (OAc >
OFm > Cl).

Thus, our results suggest that utilization of the „carboxylate strategy‟

substantially enhances the cellular efficacy of TPA compounds over cisplatin by
allowing for an optimal balance between cytotoxic and metabolic efficiency.

Introduction
The platinum based chemotherapeutic, cisplatin, is among the most commonly
used anticancer drug for the treatment of testicular, head and neck, ovarian, small cell
lung, and colorectal carcinomas.4-5 The cytotoxicity of cisplatin results mainly from the
formation of DNA crosslinks resulting in the inhibition of DNA synthesis and replication.
6-7

However, the clinical effectiveness of cisplatin is limited due to inherent cellular

resistance and dose-limiting side effects due to high levels of protein binding. 8 One
common feature among current clinical platinum therapeutics is the bis, cis orientation
of the labile leaving groups. The trans isomer of cisplatin, trans-[PtCl2(NH3)2] is much
less toxic than the cis counterparts, presumably due to its inability to form 1,2intrastrand cross links between the N7 atoms of adjacent guanines in double strand
DNA.9-10
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Although transplatin itself is clinically inactive, substitution of one of the NH 3
groups with a planar heterocyclic ligand such as pyridine, thiazole, quinoline,
isoquinoline,

etc.,

yields

a

class

of

platinum

chemotherapeutics,

called

transplanaramines (TPA‟s). These TPA compounds possess substantially enhanced
cytotoxicity profiles as compared to the “parent” trans-[PtCl2(NH3)2], with IC50 values in
the 1-10µM range across numerous tumor cell lines. Most interestingly, TPA
compounds usually exhibit no cross resistance with cisplatin or oxaliplatin and thus
demonstrate a unique cytotoxicity profile across the NCI tumor panel. 2 Although these
TPA compounds are relatively active, they are poorly water soluble and still posses high
levels of protein binding due to the lability of the chloride leaving group.
The most common modification to the TPA structures to address these issues is
through replacing the chlorides with a more stable group of carboxylate ligands. The
use of carboxylates as leaving groups for TPA‟s was first introduced to address the low
aqueous solubility of TPA‟s, but in preliminary studies showed that the „carboxylate‟
strategy could also been employed to improve the pharmacokinetic properties of mononuclear trans-platinum compounds.11 These carboxylate derivatives have shown similar
cytotoxicities to their parent chlorides.12-13 The use of carboxylate ligands also results in
increased cellular accumulation even in cisplatin and oxaliplatin-resistant cell lines.12-13
In attempts to optimize drug design, previous studies in our group have shown that the
use of formate as leaving group gives enhanced cytotoxicity in comparison to acetate. 1
In order to evaluate the in vivo properties of these TPA compounds, it is first
necessary to understand the three major factors affecting the clinical success of any
type of platinum-based cancer therapy.

These factors include the rate of cellular
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uptake, the frequency and the type of DNA adducts formed and metabolic deactivation.
Although DNA is the proposed target for a majority of platinum chemotherapeutics, the
first step in evaluating the clinical efficacy is to understand the metabolic interactions
that occur following administration. One of the most plausible targets responsible for
metabolic deactivation of platinum compounds is blood serum. Serum is the liquid
portion of blood, containing all serum proteins, at a concentration of 70 g/L.14 Among
these proteins include globulin and serum albumin. Interactions of platinum anti-tumor
compounds with sulfur containing amino acids in proteins have been shown to cause
severe nephrotoxicity in patients and are responsible for a large portion of the toxic side
effects associated with platinum based treatments.15 It is mainly accepted that once
bound to plasma proteins, platinum compounds are „deactivated‟ and eliminated from
the body.
The development of oxaliplatin and carboplatin has shown the ability of using the
carboxylate strategy to avoid these high levels of protein binding. 16-17 Although this
strategy has been used to improve the pharmacokinetic profile of cisplatin, and spurned
the development of carboplatin and oxaliplatin, the use of the cis leaving group
geometry still limits the treatment of these compounds in tumors which are currently
“platin” resistant. By extending the carboxylate strategy to TPA compounds it may be
possible to avoid high levels of protein binding while concomitantly treating tumor types
untreatable with current clinical platinum chemotherapeutics.

Results and Discussion
NMR Spectroscopy
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It has previously been seen that modifying the leaving group ligand in a series of
TPA compounds can greatly influence the rate of hydrolysis.11 To evaluate this change
in hydrolysis rate and its effect on thiol binding, NMR binding studies of TPA‟s with NAcetyl-Methionine (NAM) were performed. (Figure 2.1) The reaction of a series of a
series of TPA‟s with acetate and formate leaving groups was monitored by 1H and

195

Pt

NMR spectroscopy. As seen in (Table 2.1), the reaction of t-Pt(4-pic)NH3(OFm)2 with
NAM was followed by monitoring the H1 proton of 4-picoline and the CH proton of the
formate leaving group. Initial spectra at t = 0 show peaks at approximately δ = 8.25ppm
for the H1 of 4-picoline. The spectrum acquired at t = 4hrs of a 1:2 t-Pt(4pic)NH3(OFm)2:NAM molar ratio reaction shows a shift of the H1 of 4-picoline from δ =
8.25ppm to 8.67ppm. (Figure 2.2) After 4 hours, the peaks remained relatively
unchanged, and
sphere. The

195

Pt NMR was used to probe the resulting platinum coordination

195

Pt NMR spectra showed only one peak at δ = -3340 ppm, consistent

with a trans-bis thiol coordination to the platinum atom.18-19 Similar results were seen
with the reaction of t-Pt(Isoquin)NH3(OFm)2 with NAM, indicating the dependence of
protein binding on the formate leaving group and not the carrier ligand. (Table 2.1) The
binding rates (t1/2) of each reaction were calculated and found to be 2.6 ± 0.2 hrs for tPt(Isoquin)NH3(OFm)2 and 2.3 ± 0.1 hrs for t-Pt(4-pic)NH3(OFm)2. (Table 2.1)
The same conditions were used to probe the binding rate of t-Pt(4-pic)NH3(OAc)2
with NAM. Initial spectra at t = 0 show peaks at approximately δ = 8.30ppm for the H1
of 4-picoline. (Figure 2.3) Due to the slower rate of reactivity for the acetate ligand, the
reaction was able to be monitored by both 1H and

195

Pt NMR. The resulting

195

Pt NMR

spectra showed only one peak at t = 0hrs, δ = -1445 ppm. After 4hrs, a second peak at
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δ = -2860 ppm was observed. (Figure 2.4) This peak represents the displacement of
one acetate group by NAM, with a coordination sphere of Pt[N 2OS]. After 24hrs, the
peak seen at δ = -2860 ppm disappeared and was replaced with a peak at δ = -3325
ppm, consistent with a trans-bis thiol coordination of Pt[N2S2]. (Table 2.1) 1H NMR
spectra of the H1 of the 4-picoline revealed peaks at δ = 8.30, 8.55, and 8.70 ppm,
indicating initial compound, mono-NAM and bis-NAM species respectively. (Figure 2.3)
Similar results were seen with the reaction of t-Pt(Isoquin)NH3(OAc)2 with NAM. The
binding rates (t1/2) of each reaction were calculated and found to be 10.1 ± 1.0 hrs for tPt(4-pic)NH3(OAc)2 and 10.7 ± 0.8 hrs for t-Pt(Iso)NH3(OAc)2. (Table 2.1)
By utilizing small molecules such as NAM as a model for drug-protein binding, it
is possible to understand the contribution of the carboxylate ligand to metabolic
deactivation and therefore predict the binding to larger serum proteins such as human
serum albumin. These results show the ability of employing the carboxylate strategy as
a way to manipulate high levels of drug-protein binding with TPA compounds. These
modifications have previously been shown to play a vital role in determining the
cytotoxicity and cellular uptake of TPA compounds.20 Therefore, the general [PtN2O2]
motif could allow researchers the capability of „„ﬁne-tuning” a balance between
biological and metabolic activity of these compounds.
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Figure 2.1 Structures of trans-platinum planar amine (TPA) carboxylate compounds studied.
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Figure 2.2 NMR Spectra of t-Pt(4-pic)NH3OFm reaction with N-Acetyl Methionine
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Figure 2.3 NMR Spectra of t-Pt(4-pic)NH3OAc reaction with N-Acetyl Methionine
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Figure 2.4

195

Pt NMR Spectra of t-Pt(4-pic)NH3OAc reaction with N-Acetyl Methionine after 0hrs (A) and
4hrs (B)
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(1) The reaction of t-Pt(4pic)NH3(OAc)2 and t-Pt(Isoquin)NH3(OAc)2 with methionine was sufficiently slow
195
195
such that the mono-methionine product [Pt(N2OS)] was observed. δ Pt (ppm) = -2860 and δ Pt (ppm)
= -2895 respectively.
Table 2.1 Effects of ligand substitution on methionine binding: Reaction of each TPA compound with NAcetly Methionine was monitored by 1H and 195Pt NMR spectroscopy.
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Human Serum Albumin Binding
To evaluate the effect of leaving group stability on protein binding, cisplatin, tPt(4-pic)NH3(OFm)2 and t-Pt(4-pic)NH3(OAc)2 were incubated with human serum
albumin and allowed to react for selected time points. The extent of drug-protein binding
was analyzed by ICP-OES. Analysis of platinum content by ICP-OES shows a decrease
in free drug availability over time for all three compounds. (Figure 2.5) This time
dependent decrease in free drug availability represents a displacement of the platinumchloride or platinum-carboxylate bond and the formation of the covalent platinum-protein
adduct. As seen with the small molecule binding studies, the rate of protein binding is
directly related to the stability/lability of the leaving group.

Within 30 minutes of

incubation, approximately 25% of cisplatin was bound to serum albumin, while only 5%
of both t-Pt(4-pic)NH3(OFm)2 and t-Pt(4-pic)NH3(OAc)2 were protein bound. After 24hrs
of protein exposure, approximately 85% of t-Pt(4-pic)NH3(OAc)2, and 50% of t-Pt(4pic)NH3(OFm)2 remain unbound to serum albumin, while only 20% of administered
cisplatin remains in solution. These studies show the ability to manipulate high levels of
protein binding by modifying the stability of the carboxylate ligand.
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Figure 2.5 Effects of ligand substitution on HSA protein binding: Binding of t-Pt(4pic)NH3(OAc)2 (white), tPt(4pic)NH3(OFm)2 (grey), and Cisplatin (black) to human serum albumin over time. Compounds were
incubated with albumin (3:1) (drug:protein) and platinum content was observed by ICP-OES.

42

Effects of Protein Binding on Drug Cytotoxicity
To further understand the translatability of utilizing the carboxylate strategy to
improve the drug deactivation profile of TPA‟s, cytotoxicity assays were performed
before and after incubation of TPA‟s with whole serum in A2780 ovarian carcinoma cell
lines. Cisplatin, t-Pt(4-pic)NH3(OFm)2 and t-Pt(4-pic)NH3(OAc)2 were incubated with
whole serum for 0hr and 24hr and drug cytotoxicity was then examined.

Cisplatin

shows a complete loss of cytotoxicity upon incubation with serum for 24hrs, with an
observed IC50 increase of >30 fold. (Table 2.2)

Cellular treatment with t-Pt(4-

pic)NH3(OFm)2 and t-Pt(4-pic)NH3(OAc)2 after 24hr incubation with whole serum show
only a 3-fold and 2-fold increase in IC50 value respectively. (Table 2.2) Although less
cytotoxic in the control, once administered, a majority of the cytotoxic action of cisplatin
is lost within a very short time due to interactions with serum proteins in the blood
stream. In contrast, the cytotoxicity of t-Pt(4-pic)NH3(OFm)2 and t-Pt(4-pic)NH3(OAc)2 is
retained after serum incubation. The rate of drug deactivation is directly related to the
rate of hydrolysis, as the –OFm ligand is more labile than the –OAc ligand, which are
both more stable than –Cl. Utilizing the bis-trans-geometry of the carboxylate groups
provides little driving force for ligand substitution. This finding shows a class of drugs
with significantly longer plasma half lives and decreased drug deactivation over current
clinical platinum based chemotherapeutics.
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Table 2.2 Effects of serum binding on efficacy of trans-platinum compounds in A2780 ovarian carcinoma
cells. Platinum compounds were incubated with whole serum for 24hrs and compared to control.
Cellular grown inhibition was then measured by MTT after treatment.
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Effects of Protein Binding on Cellular Accumulation
Since the rate of cellular uptake and total accumulation correlates to the cytotoxic
effect of platinum drugs, cellular accumulation of each platinum compound, before and
after whole serum treatment, was examined. Treatment of A2780 cells with 10µM
cisplatin produced an increase in cellular platinum levels reaching approximately 130
attomole Pt/cell after 24hrs.

In contrast, cells treated with cisplatin, after a 24hr

incubation period with whole serum prior to treatment, showed a drug accumulation of
30 attomole Pt/cell. (Figure 2.6) Cellular treatment with 10µM t-Pt(4-pic)NH3(OFm)2
also shows a decrease in overall platinum accumulation after serum incubation, 310
attomole Pt/cell in the control and 150 attomole Pt/cell after 24hr serum treatment.
Serum pretreatment with 10µM t-Pt(4-pic)NH3(OAc)2 shows no significant decrease in
overall platinum content as compared to the control; 90 attomole Pt/cell in both the
control after 24hr serum incubation. (Figure 2.6) While the serum pretreatment of tPt(4-pic)NH3(OFm)2 results in a decrease in cellular uptake, the overall decrease in
cellular uptake is only 2-fold, as compared to a 4-fold decrease for cisplatin. Once again
the same trend is seen, where an increase in leaving group lability, Cl > OFm > OAc,
results in increased protein binding and thus, a decrease in cellular uptake.

By

minimizing interactions with serum proteins, TPA compounds have the ability to
maintain high levels of cellular uptake and thus a greater level of cytoxocity over
metabolic deactivation.
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Figure 2.6 Influence of protein binding on platinum cellular uptake in A2780 ovarian carcinoma cells.
A2780 Cells were treated with 10µM cisplatin, t-Pt(4-pic)NH3(OFm)2 and t-Pt(4-pic)NH3(OAc)2 before and
after serum pretreatment for 24hrs. After 24hr cellular treatment of each compound, cells were removed
from the plate and analysis of platinum content was performed on a Varian ICP-MS. Values are the
average (+/- S.E.M.) of three independent experiments.
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Effects of Protein Binding on DNA Platination
The cytotoxicity of platinum chemotherapeutics is mainly accepted to be
modulated by the frequency and type of platinum-DNA adducts formed during drug
treatment. Upon treatment, TPA compounds promote DNA strand breaks, interstrand
cross-links and ultimately trigger the apoptosis cascade, resulting in programmed cell
death.1 To examine the role of protein binding on the levels of DNA platination, A2780
cells were treated for 24hrs with 10µM cisplatin, t-Pt(4-pic)NH3(OFm)2 and t-Pt(4pic)NH3(OAc)2 before and after serum pretreatment. DNA platination levels after 24
hours of continuous cisplatin treatment reached approximately 675 nmole Pt/g DNA,
while platinum levels of cisplatin pretreated with whole serum remained less than 40
nmole Pt/g DNA. (Figure 2.7) The same trend in DNA adduct formation, albeit at a
lesser extent, was seen with t-Pt(4-pic)NH3(OFm)2, with platinum levels reaching 245
nmole Pt/g DNA in the control and 70 nmole Pt/g DNA after pretreatment with serum.
(Figure 2.7) In contrast, DNA platination levels after 24 hours of continuous t-Pt(4pic)NH3(OAc)2 treatment remained constant in both the control and after 24hrs of serum
pretreatment, with levels reaching approximately 70 nmole Pt/g DNA.

While initial

platination levels of both t-Pt(4-pic)NH3(OFm)2 and t-Pt(4-pic)NH3(OAc)2 are lower than
seen with cisplatin, after 24hrs of serum pretreatment, both t-Pt(4-pic)NH3(OFm)2 and tPt(4-pic)NH3(OAc)2 outperform cisplatin and retain a large portion of their cytotoxic
profile.
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Figure 2.7 Influence of protein binding on DNA platination in A2780 ovarian carcinoma cells. A2780 Cells
were treated with 10µM cisplatin, t-Pt(4-pic)NH3(OFm)2 and t-Pt(4-pic)NH3(OAc)2 before and after serum
pretreatment for 24hrs. After 24hrs of drug exposure, cells were removed from the plate and washed with
PBS. Cellular DNA was then extracted and analysis of platinum content was performed on a Varian ICPMS. Values are the average (+/- S.E.M.) of three independent experiments.

48

Conclusion
The development of novel cytotoxic transplatin compounds provides for
promising treatment of clinical “platin” drug resistant tumors. By understanding the
balance between cytotoxic activity and metabolic deactivation it is possible to defer
many of the toxic side effects associated with chemotherapeutics, and thus provide for
substantial increases in mean tolerated dosages. Here, we evaluate the ability of using
carboxylate ligands to modulate the reactivity of TPA compounds towards sulfur
containing proteins. We have found that by increasing the stability of the leaving group
leads to decreased protein binding and thus allows for increase cytotoxic activity after
pre-incubation with serum proteins. The acetate ligand was shown to be the most
stable, followed by the formate and chloride, respectively. Although the stability of the
acetate group ultimately provides for the least reactivity towards proteins, this enhanced
stability also provides for decreases in DNA binding and therefore a slightly less potent
IC50 is seen when compared with the formate derivative.

These results show the

importance of understand the balance between cytotoxicity and metabolic deactivation.
The use of carboxylates in this process ultimately provides the means to “fine-tune” the
reactivity of trans-platinum compounds and therefore provides a balance between the
cytotoxic and pharmacokinetic profiles.

Methods
Materials
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All compounds were synthesized according to methods reported previously.

1,11,20

Albumin from human, 99% and N-Acetyl Methionine was purchased from Sigma. Fetal
Bovine Serum (FBS) was purchased from Atlanta Biologicals.

NMR Spectroscopy
A stock solution of both deuterated (DPBS) and normal (PBS) phosphatebuffered saline ([phosphate] = 150 mM, pH 7.35 at 37° C, [NaCl] = 120 mM, [KCl] = 2.7
mM) was prepared for all reaction solutions to mimic physiological conditions. Platinum
compounds were incubated with N-Acetyl-Methionine at a reaction ratio of 1:2 (Platinum
Complex : N-Acetyl-Methionine) at 37oC. 1H NMR and 195Pt NMR spectra were recorded
at various time points up to 24hrs. 1H NMR and

195

Pt NMR spectra were recorded on a

Varian Mercury series 300 MHz NMR spectrometer using a 5 mm probe for 1H and a 10
mm broad-band probe for

195

Pt. 1H spectra were referenced to sodium 3-(trimethylsilyl)-

propionate (TSP) at δ = 0 ppm, and

195

Pt spectra were referenced to Na2[PtCl6]. The

scanning frequency for 195Pt nuclei was set at 64.32 MHz.

Human Serum Albumin Binding
For HSA binding, 50μL of 1.8mM solutions of each complex were prepared in
PBS, pH 7.4 and added to 50μL of 0.6 mM HSA such that the final drug concentration
was 0.9 mM. (3:1; Drug:HSA) The reactions were incubated at 37 °C for 0, 0.5, 2, 6,
and 24 hours.

Unreacted drug was removed by centrifugation through a Millipore
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Microcon YM-10 (10,000 kDa) membrane filter at 14,000xg for 30 min. The centrifuge
cup was upturned in a second eppendorf and centrifuged at 1000xg for 3 min to isolate
the protein-bound drug. The digestion procedure followed published methods. 21
Analysis of platinum content for both the protein-bound and unreacted samples was
performed on a Varian ICP-OES.

Cellular Growth Inhibition
The MTT assay was used to determine growth inhibition potency of platinum
drugs before and after incubation with FBS.22 A2780 cells were seeded in 96-well
plates at 6,500 cells/well in 200μL RPMI 1640 media supplemented with 10% FBS and
1% Penicillin:Streptomycin and allowed to attach overnight. Media was removed and
200µL of each compound was added after serial dilution in quadruplicate wells and
exposed to cells for 72h. For time dependent media incubation studies 500µM of each
Pt compound was incubated in FBS (1:10 v/v) for 24hrs before cellular treatment.
Samples were diluted to treatment concentrations with fresh media and exposed to cells
for 72hrs. After 72hrs, drug solution was removed and plates were washed with PBS.
100µL of 5mg/mL MTT solution was added and solution was incubated with cells for 3h
at 37oC. After incubation, MTT solution was removed and 100µL of DMSO was added.
Quantification of cell growth in treated and control wells was then assessed by
measurement of absorbance at 562nm. IC50 values were determined graphically.

Cellular Uptake of Drug Complexes
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A2780 cells were plated in 10cm dishes at 2 million cells/dish and allowed to
attach overnight. Cells were then treated with 10µM of each drug for 24hrs before and
after serum incubation. After 24hrs, drug solution was removed and plates were washed
3x with PBS. Cells were then removed from the dish with trypsin and centrifuged for
5min at 1000xg. Media was removed, cell pellet was washed three times with PBS, cells
were counted and resuspended in 250μL of ddH20. Samples were digested following
published methods.21

Analysis of Pt content was performed on a Varian ICP-MS.

Standards and blank were prepared similarly.

Quantification of DNA-Drug Adducts
A2780 cells were plated in 10cm dishes at 2 million cells/dish and allowed to
attach overnight. Cells were then treated with 10µM of each drug for 24hrs before and
after serum incubation. After 24hrs, drug solution was removed and plates were washed
3x with PBS. Cells were then removed from the dish with trypsin and centrifuged for
5min at 1000xg. Media was removed, cell pellet was washed three times with PBS and
suspended in 250μL of ddH20. DNA was extracted using a DNeasy blood and tissue kit
(Qiagen) according to the manufacturer‟s protocol.

Extent of DNA platination was

measured on a Varian ICP-MS.
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Abstract
The interactions of various polynuclear platinum complexes with mouse plasma,
human plasma, and human serum albumin were studied. Some of the compounds
examined were the “non-covalent” analogs of the trinuclear BBR3464 as well as the
dinuclear compounds differing in only the presence or absence of a central –NH2–+
(SET3007 and analogs). The rate and extent of platinum-protein adduct formation was
monitored by ICP-OES and evidence for pre-association, presumably through
electrostatic and hydrogen-bonding, was obtained by fluorescence spectroscopy and
through the use of methionine and cysteine blocked human serum albumin. In the case
of those compounds containing Pt-Cl bonds, further reaction took place presumably
through displacement by sulfur nucleophiles, while the non-covalent derivatives showed
an initial formation of a platinum-protein complex, but no change in complex formation
over time.

The implications for protein pre-association and plasma stability of

polynuclear platinum compounds, both covalent and non-covalent are discussed.
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Introduction
There are four main factors which control the pharmacokinetics of compounds in
biological systems. These factors include but are not limited to, absorption, distribution,
metabolism, and elimination. These four criteria greatly affect the bioavailability and
kinetics of drug exposure towards the biological system of interest. Absorption refers to
the ability of a drug, following administration, to effectively reach the systemic
circulation; either by passing through intestinal cell membranes in the case of orally
administered compounds or other natural membranes such as the blood brain barrier.1
Once in systemic circulation, the process of metabolism begins to decompose the
compounds of interest into drug metabolites. If the metabolites of the compound are
„inert‟ after metabolism, a large portion of the pharmacological effect is thus diminished
and the drug administered can no longer be distributed to the site of action. Metabolism
can occur by reactions with liver redox enzymes such as cytochrome P450 and through
interactions with proteins in the blood stream.2 Prolonged elimination half-lives can
result in reduced tolerability of the administered drug in patients, often warranting
removal of compounds of interest from clinical trials. About ¾ of drug candidates do not
enter clinical trials due to pharmacokinetics problems in animals. Also, about 40% of
molecules that fail in clinical trials do so because of pharmacokinetics problems.2
Therefore, these points ultimately control the outcome of drugs introduced into the
clinics.
One

drug

which

encountered

pharmacokinetic problems

via

metabolic

interactions in the clinical setting is the anti-tumor agent BBR3464 (Figure 3.1).
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BBR3464, a novel tri-platinum compound, has demonstrated promising activity in
cisplatin-resistant, cisplatin-sensitive and p53 mutant tumors. BBR3464 is also forty to
eighty fold more potent on a molar dose basis than its predecessor and most commonly
used platinum anticancer agent cisplatin, c-DDP (Figure 3.1). Although providing
promising pre-clinical and Phase I clinical studies, in Phase II studies BBR3464 showed
higher plasma protein binding in human than mice and a more rapid degradation of
BBR3464 into inactive metabolites. These pharmacokinetic factors, along with reduced
activity in gastric and lung cell carcinomas, have discouraged the use of BBR3464 in
the clinical setting.3-7 Therefore, there is a need for the development of novel platinum
compounds to circumvent these factors.
Synthesis, characterization, and biological evaluation of a large variety of novel
polynuclear platinum anti-cancer drug candidates have taken place since the
introduction of BBR3464 into the clinics in the late „90s. 8-12

Polynuclear platinum

compounds which employ polyamine linkers of variable chain length represent a new
class of anti-tumor agents showing activity profiles different from c-DDP.13-14 These
drugs use a „covalent‟ mode of DNA binding, similar to c-DDP by displacement of the
Pt-Cl bond and formation of a coordinate Pt-DNA adduct. Due to the ease of
aquatablility of the –Cl leaving group, subsequent Pt-protein bond formation is still a
prevalent problem, thus diminishing the overall effect of platinum chemotherapeutic
compounds. Replacement of the -Cl leaving groups with substitutionally „inert‟ NH3
ligands introduces an entirely novel class of „non-covalent‟ polynuclear platinum
compounds. (Figure 3.2 (AH44 and TriplatinNC)) The presence of hydrogen-bonding
and electrostatic interactions contributes to the unique profile of this group of drugs.
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The presence of a charge in the linker, either as the central tetra-amine unit of a
trinuclear compound or through a polyamine linker in a dinuclear species, greatly
enhances anti-tumor activity for this „non-covalent‟ class.15
Although DNA is the core target for the vast majority of platinum anti-cancer
compounds, the first step in probing the clinical effectiveness of these drugs is to fully
understand the metabolic interactions that may occur with these compounds while
traveling through the systemic circulation towards their desired site of action. From a
solely chemical standpoint, these metals, following aquation, would be expected to act
as soft Lewis acids and to form stable complexes with S or N donors found in proteins.16
Thus, the rate of hydrolysis of the leaving ligand greatly affects the amount of protein
binding. Albumin, the most abundant plasma protein and the most likely candidate for
drug metabolic interactions, is a 585 amino acid, 66 kDa, single chain protein involved
in transportation of numerous drugs and ligands.17-18 HSA is largely α-helical and
contains 17 disulfide bridges and only one free cysteine, Cys34. This residue, along
with Met298 is speculated as the primary binding sites of c-DDP.19 It is mainly accepted,
in the case of most Pt-compounds, that once coordinated to S or N donors in plasma
proteins or other biomolecules, platinum compounds are effectively „deactivated‟ and
eliminated from the body; thus never reaching their desired site of action.20 Severe
nephrotoxicity has also been associated with interactions of platinum anti-tumor
compounds with thiol groups of proteins.21-22
In an effort to improve the therapeutic efficiency, by minimizing interactions with
plasma proteins, novel formulations of platinum compounds have been developed [46].
One pathway to minimize metabolic interactions can be through replacement of the
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most commonly used –Cl leaving group with other, more stable ligands.

Cell

Therapeutics Inc. (CTI) is currently evaluating a derivative of the polynuclear platinum
compound BBR3610 and has shown that replacement of the –Cl ligand with a
carboxylate, such as butyrate or capronate, results in much lower plasma binding in
vitro, while still retaining its cytotoxicity profile in vivo.23 In this sense, it is possible to
minimize the extent of protein binding by modifying the labile leaving group attached to
the platinum moiety.
A study of the interactions of BBR3464 and other polynuclear platinum drugs
(Figure 3.1, 3.2) with plasma proteins such as albumin has not been as thoroughly
investigated as have the interactions with glutathione and other biomolecules. As one of
the major contributors to Pt-S binding, albumin, and more specifically its interactions
with platinum compounds must be investigated and the pharmacokinetics of these
potential drug candidates‟ interactions understood. An understanding of the effects of
ligand substitution rates and geometry contribution can also provide new tools to aid in
drug discovery and development. The long term goal is therefore to evaluate,
understand, and improve the pharmacokinetic profile of platinum chemotherapeutics in
an attempt to prevent drug deactivation and diminish toxic side effects thus, facilitating
the better development of platinum compounds for the treatment and prevention of
cancer.
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Figure 3.1 Chemical Structures of Cisplatin and Polynuclear Platinum Compounds.
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Figure 3.2 Chemical Structures of Selected Polynuclear Platinum Compounds.
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Results and Discussion
Mouse Plasma Binding with Selected -Cl Polynuclear Platinum Compounds
Plasma is the liquid portion of blood, approximately 55% of the total volume, not
including red or white blood cells, in which all plasma proteins are contained.20 Among
these proteins include fibrinogen, globulins, and human serum albumin (HSA). Due to
the discrepancy found between levels of protein binding in mouse plasma and human
plasma with BBR3464, it was necessary to first evaluate the binding of selected
polynuclear platinum compounds with mouse plasma. Cisplatin, BBR3464 and
BBR3610 were incubated with rehydrated mouse plasma for 0-24 hrs and the extent of
platinum-protein binding was analyzed by ICP-OES. (Figure 3.3) Binding of Cisplatin,
BBR3464 and BBR3610 to plasma proteins was found to increase with time, which can
be expected as Pt-Cl bond dissociation occurs and Pt-protein bond formation increases.
Percentages noted on all data represent the percentage of “free-drug” available, drug
that has not been deactivated due to protein binding. It is worth observation that c-DDP
shows a much higher free drug percentage at all time points than do BBR3464 and
BBR3610. This interaction could be a result of the high charge associated with both
BBR3610 and BBR3464. In the early time points, there is an immediate interaction with
the protein, much faster than can be accounted for with only Pt-Cl bond displacement.
This initial decrease in free drug availability is a combination of both electrostatic charge
interactions and covalent Pt-protein bond formation. Due to this high charge, BR3464
shows much higher plasma binding over time than cisplatin.
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Figure 3.3 Effects of mouse plasma binding on drug availability. Cisplatin, BBR3464 and BBR3610 were
incubated with mouse plasma for selected time points and platinum content for protein bound and free
drug was analyzed by ICP-OES.
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Human Plasma Binding with Selected Polynuclear Platinum Compounds (PPC‟s)
Further evaluation of a larger group of PPC‟s was continued by investigating the
binding between PPC‟s and human plasma. Compounds included in this study provided
for the analysis of differences in charge and leaving group lability on Pt-protein binding.
Cisplatin and BBR3464 were first analyzed to confirm the discrepancy found between
binding in mouse plasma and human plasma with BBR3464 in the clinics. At the 0.5hr
time point, in mouse plasma and human plasma, the percentage of unbound c-DDP
was approximately 70%-80%, while the percentage of unbound BBR3464 was 35% in
mouse plasma but only 15% in human plasma. Similar observations can be made at
subsequent time points. (Figure 3.4) BBR3610 shows a slower rate of protein binding as
compared to BBR3464, but after 24hrs the overall amount of free drug available is still
less than 10%. Figure 3.5 shows the effects of addition of -Boc and -Dach groups, used
to decrease overall charge and mimic oxaliplatin structure respectively, on the rate of
drug-protein binding. By adding the -Dach chelate in place of the bis ammonia carrier
ligands, the position of the chloride is thus shifted to the –cis position. Although in the –
cis position, the amount of protein binding is ultimately unchanged as compared to the
parent BBR3610 complex. This trend is also seen with the addition of –Boc alone, and
in combination with –Dach (BBR3610-Dach-Boc) Both of these drug derivatives show
similar levels of protein binding as BBR3610. Also shown in Figure 3.5 is the effect of
ligand substitution of protein binding. Due to decreased hydrolysis rates caused by
substitution of -Cl for -NO2, protein binding in BBR3610-NO2 is significantly lower than in
the case of BBR3610 at similar time points. Free drug percentage in the case of
BBR3610-NO2, approximately 30% after 24hrs, shows a significant improvement over
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BBR3464, BBR3610 and also cisplatin. Although substitution of –Cl for –NO2 has
proven to be not clinically relevant, the concept of ligand substitution based on
decreasing hydrolysis rates has shown that a decrease in metabolic activity is
accessible through ligand substitution.

These results were also observed with the

SET3007 series. (Figure 3.6) Therefore the driving force behind the extent and rate of
drug protein interactions are a direct result of the stability of the leaving group. This
result gives support to further investigate the effect of leaving group ligands on the
binding on PPC‟s to plasma proteins.
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Figure 3.4 Effects of human plasma binding on drug availability. Cisplatin, BBR3464 and BBR3610 were
incubated with human plasma for selected time points and platinum content for protein bound and free
drug was analyzed by ICP-OES.
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Figure 3.5 Human Plasma Binding with BBR3610 and derivatives. Compounds were incubated with
human plasma for selected time points and platinum content for protein bound and free drug was
analyzed by ICP-OES.
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Figure 3.6 Human Plasma Binding with SET3007 and derivatives. Compounds were incubated with
human plasma for selected time points and platinum content for protein bound and free drug was
analyzed by ICP-OES.
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Significance of Electrostatic Interactions on Human Serum Albumin Binding
The role of pre-association in dictating the final products of reactions of PPCs
with biomolecules has been assisted greatly in the trinuclear case by the synthesis and
evaluation of “non-covalent” analogs where the Pt–Cl bonds are displaced by a
substitution-inert NH3 or a “dangling” amine H2N(CH2)6NH3+. In order to better
investigate these types of interactions, human serum albumin (HSA) was selected as
the protein of interest.

Human serum albumin is a versatile transport protein and

receptor for a variety of ligands and drugs. The primary function of HSA is the transport
of fatty acids but since it carries a negative 17 charge, it is also responsible for shuttling
a wide variety of metal ions, steroids, and a variety of pharmaceuticals. 24-25 HSA
constitutes roughly 60% of the mass of plasma proteins with a concentration of ∼40
mg/mL. It is highly likely therefore that HSA binding could contribute to these metabolic
deactivation reactions, as suggested also for some similar dinuclear complexes.10 To
evaluate and quantitate the binding of PPC‟s to HSA, BBR3464, BBR3610, Cisplatin,
AH44 and TriplatinNC were incubated and the ultrafilterable protein unbound fraction
was quantified for selected time points.(Figure 3.7) Analysis by ICP-OES shows a
decrease in Pt content immediately upon mixing, t = 0, for all compounds, excluding
cisplatin. This initial decrease in Pt content represents the non-covalent, “preassociation” of the Pt complex with protein. The Pt content corresponding to compounds
containing a Pt-Cl bond decreases with time, representing a displacement of the Pt–Cl
bond and a formation of the coordinate/covalently bound Pt–protein species (where
covalent is used to indicate Pt–amino acid residue formation independent of strict
contributions of covalent or coordinate bonding). In contrast, ICP-OES analysis of AH44
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and TriplatinNC shows a constant Pt concentration from t = 0 through t = 24 h. Due to
the presence of the substitution-inert –NH3 group, the initial pre-association is not
followed by a covalent Pt–protein interaction. The results for AH44 and TriplatinNC
suggest that these non-covalent compounds may “by-pass” the deactivation associated
with Pt–S bond formation.
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Figure 3.7 “Pre-Association” Effects and Significance of Electrostatic Interactions on Human Serum
Albumin Binding: Compounds were incubated with human serum albumin for selected time points and
platinum content for protein bound and free drug was analyzed by ICP-OES.
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HSA Protein Modification and Binding Site Evaluation
Previous studies on the identification of the cisplatin binding site on HSA have
been shown to be a combination of both free sulfur containing amino acids, Cys-34 and
Met-298.19,26-27 Although HSA contains 35 cysteine amino acids, 34 are involved in
disulfide bridges and only one free cysteine remains. As seen in the Figure 3.8, both
Met-298 and Cys-34 are located on the solvent accessible surface of HSA and are valid
candidates for the binding of platinum chemotherapeutics. In the case of BBR3464, the
addition of a high charge component could cause the drug to specifically or
preferentially bind to one amino acid or another. Therefore, in this regard, we examined
the role of amino acid blocking and its effect on the binding of BBR3464 to native and
modified HSA. BBR3464 was incubated with Cysteine and Methionine blocked HSA
and the reaction was monitored by ICP-OES.(Figure 3.9) Cysteine blocked HSA shows
equal amounts of free drug after each time point as the native HSA protein. This
suggests that Cysteine binding does not play a major role in the binding of BBR3464 to
HSA. On the other hand, after the blocking of Methionine residues, Pt-protein bond
formation is effectively eliminated. This suggests that Met residues on HSA are the
major contributor of Pt deactivation for BBR3464. Also, it is important to note that even
after blocking methionine residues on HSA, approximately 20% of administered
BBR3464 interacts with the protein. This effect is the pre-association of the positively
charged drug, presumably, with negative regions of HSA.
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Figure 3.8 Crystal structure of human serum albumin with Met-298 and Cys-34 highlighted in red. Figure
adapted from PDB ID: 1BM0
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Figure 3.9 Effects of cysteine and methionine peptide blocking on BBR3464-HSA binding. Compounds
were incubated with human serum albumin for selected time points and platinum content for protein
bound and free drug was analyzed by ICP-OES.
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Effects of Charge on HSA Global Conformation
As seen in Figure 3.10, the charge density map of HSA shows multiple regions of
negative charge, shown in red, where the cationic platinum compounds could first
interact and subsequently bind to S-containing amino acids.

To understand and

examine these changes, fluorescence spectroscopy was utilized.

The fluorescence

from excitation of HSA at 298nm reflects changes in the microenvironment of the
tryptophan 214 residue, serving as a tool to obtain information about conformational
changes of the protein.28 A decrease in fluorescence of the lone tryptophan of HSA is
interpreted as a conformational change making the amino acid more accessible to water
quenching. The covalent binding and cationic BBR3464, was used to investigate these
interactions. Upon incubation with BBR3464, HSA fluorescence was shown to decrease
over time with an approximate 16% decrease in overall fluorescence after 72hrs.
(Figure 3.11A) The same trend in fluorescence decrease of HSA is also seen in the
chemically modified HSA series.

Figure 3.11B shows the influence of the charged

portion of drug binding on the overall conformation of the methionine blocked protein;
with a decrease in fluorescence of approximately 17%. The interaction of BBR3464
with methionine blocked HSA in nearly identical as seen in native HSA, which shows a
fluorescence decrease of 16%. Although not covalently bound to methionine blocked
HSA, the charge portion of BBR3464 associates with the surface of the protein, causing
perturbations in the global HSA structure. The same trend is seen with the interactions
of BBR3464 and cysteine blocked HSA, with an overall fluorescence decrease of 14%.
(Figure 3.11C) Therefore the decrease in fluorescence represents global changes in
the structure of HSA upon BBR3464 electrostatically binding to the surface of albumin.
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To this extent, fluorescence spectroscopy provides a means to analyze the effect of
charge on the binding between HSA and PPC‟s, independent on the covalent or noncovalent nature of the final platinum-protein adduct.
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Figure 3.10 Charge density structure of human serum albumin with positive regions shown in blue and
negative regions shown in red. Figure adapted from PDB ID: 1BM0
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Figure 3.11 Electrostatic Effects on HSA Global Structure. BBR3464 was incubated with HSA,
methionine blocked HSA, and cysteine blocked HSA for 0, 24, 48, and 72hrs. Top spectrum represents
protein before addition of BBR3464. Bottom spectrum represents complex formed after 72hr reaction.
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Conclusion
In this contribution we examine the reactions of polynuclear platinum compounds
with plasma and human serum albumin (HSA). We show for the first time the presence
of a pre-associated or “noncovalent” interaction of a platinum drug on the protein, as
well as a method to possibly reduce drug protein interactions by ligand substitution.
These studies suggest that the non-covalent compounds, AH44 and TriplatinNC may
“by-pass” the deactivation associated with Pt–S bond formation. This is especially
important for TriplatinNC as this 8+ compound is taken up into cells in a significantly
greater concentration than either BBR3464 or AH44, and as a result has demonstrated
in vitro cytotoxicity equivalent to cisplatin. The “non-covalent” compounds have shown a
new mode of DNA binding distinct from intercalation and minor-groove binding. As
these reactions with plasma, and especially with HSA, are generally considered
responsible for the metabolic deactivation of platinum-based drugs, understanding the
biophysical aspects of such interactions may allow for strategies to manipulate their
extent with consequent effects on cellular uptake and even therapeutic index.

Materials and Methods
Materials
All platinum compounds were synthesized according to methods reported previously.
11,29-30

Human plasma was purchased from Innovative Research Inc. Dehydrated

citrated mouse plasma and Albumin from human serum, minimum 99%, Nethylmaleimide, and Iodomethane, were obtained from Sigma-Aldrich (St. Louis, MO).
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Mouse Plasma Binding
Dehydrated citrated mouse plasma was purchased from Sigma Aldrich and
reconstituted in accordance with the manufacturer‟s directions. Complex solutions were
prepared in sterilized water and added to mouse plasma such that the final
concentration of complex was 0.9 mM. The mixtures were reacted at 37 °C for 0, 0.5, 2
and 24 hours in the dark, then centrifuged through a Microcon YM-10 10,000 kDa
membrane filter at 14000 g for 10 min to isolate the ultrafiltrate. The centrifuge cup was
upturned in a second eppendorf and then centrifuged at 1000 g for 3 min to isolate the
protein-bound fraction. The samples were stored at -20 °C prior to digestion. Analysis
was performed on a Varian ICP-OES.

Human Plasma Binding
Solutions of each drug were prepared in PBS and added to human plasma such that the
final concentration of complex was 0.9mM (1:1 v/v). The reactions were incubated at
37 °C for 0, 0.5, 2 and 24 hours.

Unreacted drug was removed by centrifugation

through a Millipore Microcon YM-10 (10,000 kDa) membrane filter at 14,000xg for
30 min. The centrifuge cup was upturned in a second eppendorf and centrifuged at
1000xg for 3 min to isolate the protein-bound drug. Both ultrafiltrate and protein samples
were stored at -20°C immediately following centrifugation. The digestion procedure
followed published methods.29 Analysis of platinum content for both the protein-bound
and unreacted samples was performed on a Varian ICP-OES. Protein concentration
was determined by the Bradford method with human serum albumin as the standard.31
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Human Serum Albumin Protocol
1.8mM solutions of each complex were prepared in phosphate buffer and added to 0.6
mM HSA such that the final concentration of complex was 0.9 mM. (3:1; complex:HSA)
The mixture was reacted at 37 °C and 100μL aliquots were removed at t=0, 0.5, 2, 6,
and 24 hours. Aliquots were then centrifuged through a Microcon YM-10 10,000 kDa
membrane filter as described above.

HSA Protein Modification and Binding Site Evaluation
Cys-34-blocked HSA was prepared by incubation of albumin solution in 100 mM
ammonium bicarbonate, pH 7.9, with 2 mol eq of N-ethylmaleimide for 24 h at ambient
temperature in the absence of light. Methionine residues were methylated by reaction
with iodomethane. Iodomethane in 500-fold molar excess was added to an HSA
solution in 0.1 M citric acid-phosphate buffer, pH 4.0. The solutions were stirred at
ambient temperature for 24 h in the dark. Blocking reagents were removed by
centrifugation through a 10,000MW membrane filter. Concentrated protein sample was
then redissolved in ddH2O and lyophilized.

Fluorescence Binding Studies with Chemically Modified HSA
Fluorescence Binding Studies were performed on Native HSA, Cys-Modified HSA, and
Met-Modified HSA in an attempt to determine the influence of amino acid availability on
BBR3464 binding. Fluorescence measurements were conducted on a Cary Eclipse
Fluorimeter with the excitation and emission wavelengths set at 279 and 310 nm,
respectively, with a scan rate 120 of nm min−1. The reactions of platinum compounds
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were studied at 10:1 (Pt:HSA). An initial concentration for a 10:1 reaction was prepared
for each drug. Separate measurements were taken at t = 0 and appropriate time
intervals.

Fluorescence Spectroscopy
Fluorescence measurements were conducted on a Cary Eclipse Fluorimeter with the
excitation and emission wavelengths set at 280 and 320 nm, respectively, with a scan
rate of 120 nm/min. The reaction of TriplatinNC was studied at reactant ratio of 1:1
(Drug:HSA). Each sample was allowed to react for the stated time at 37oC before the
measurement was taken. Separate measurements were taken at t = 0 and appropriate
time intervals.
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Abstract
Although the cytotoxic effects of clinical platinum based chemotherapeutics result
mainly from damaging drug-DNA adducts, the overall efficacy of these drugs is limited
by metabolic deactivation through covalent drug-protein binding. In this study the effects
of glutathione, human serum albumin (HSA) and whole serum binding with cisplatin,
BBR3464, and TriplatinNC, a “noncovalent” derivative of BBR3464 were investigated.
Specifically, we ask whether these interactions can influence the efficacy of TriplatinNC,
including cytotoxicity, levels of cellular accumulation, DNA adduct formation, and
intracellular distribution. After 48 hours of treatment with buthionine sulphoximine
(BSO), the cellular glutathione level was reduced and cisplatin and BBR3464-induced
apoptosis was augmented. In contrast, TriplatinNC-induced cytotoxicity was unaltered
by inhibiting glutathione synthesis. Treatment of A2780 ovarian carcinoma cells with
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HSA bound cisplatin (cisplatin/HSA) and cisplatin pre-incubated with whole serum show
dramatic decreases in cytotoxicity, cellular accumulation, and DNA adduct formation
compared to treatment with cisplatin alone.

Treatment with HSA bound BBR3464

(BBR3464/HSA) and BBR3464 pre-treated with whole serum also show a drastically
reduced cytotoxic profile, and significantly less DNA platination.

In contrast,

TriplatinNC, the HSA bound derivative (TriplatinNC/HSA), and TriplatinNC pre-treated
with whole serum retained identical cytotoxic profiles and equal levels of cellular
accumulation at all time points. Confocal microscopy of TriplatinNC-NBD, a fluorescent
derivative of TriplatinNC, and TriplatinNC-NBD/HSA both show nuclear/nucleolar
localization patterns, distinctly different from the lysosomal localization pattern seen with
HSA. Cisplatin-NBD, a fluorescent derivative of cisplatin, was shown to accumulate in
the nucleus and throughout the cytoplasm while the localization of Cisplatin-NBD/HSA
was limited to lysosomal regions of the cytoplasm. The results suggest that TriplatinNC
can avoid high levels of metabolic deactivation currently seen with clinical platinum
chemotherapeutics, and therefore retain a unique cytotoxic profile after cellular
administration.

Introduction
Platinum drugs are among the most commonly used chemotherapeutics for the
treatment of testicular, head and neck, ovarian, small cell lung, and colorectal
carcinomas

1-3

. The cytotoxicity of cisplatin is accepted to result mainly from the

formation of bifunctional DNA crosslinks resulting in the inhibition of DNA synthesis and
replication.4 The DNA-reactive platinum species are considered to be monoaquo and
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diaquo complexes – in general [Pt(amine)2(H2O)2]2+ or [Pt(amine)2(Cl)(H2O)]+ produced upon hydrolysis of the administered drugs, and the chemistry of these species
has been well examined.5 While this concept has been useful in rationalizing some
structure-activity relationships, there is increasing understanding that even anions with
nominally weak affinity for platinum – CO32-

6-7

; SO42- 8; PO43- and even RCOO-

9

-

become physiologically relevant ligands because of their high concentrations in plasma
and cells. Similarly, cellular accumulation of platinum drugs is multifactorial with
evidence for both passive and active transporter-mediated processes.10
The three major pharmacological factors affecting the clinical success of any type
of platinum-based cancer therapy are cellular uptake, the frequency and the type of
DNA adducts formed and metabolic deactivation. Metabolic deactivation is also
mediated through interactions of the small molecules with biomolecules, specifically
sulfur-containing amino acids in proteins, and these interactions may contribute to the
toxic side effects associated with platinum based treatments. 11-12 One of the most
plausible extracellular non-DNA targets for platinum compounds is blood serum. Serum
is the liquid portion of blood, approximately 55% of the total volume, excluding red and
white blood cells, containing all plasma proteins at a concentration of 70 g/L. 13 These
proteins include fibrinogen, globulins, and human serum albumin (HSA). Albumin, the
most abundant serum protein at 30-50g/L and the most likely protein candidate for drug
metabolic interactions, is a 585 amino acid, 66 kDa, single chain protein involved in
transportation of numerous drugs and ligands

14-15

. It is mainly accepted that once

coordinated to plasma proteins, platinum compounds are effectively „deactivated‟ and
eliminated from the body; thus never reaching their desired site of action

16-17

.
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Another important sulfur-containing protein found intracellularly is the tripeptide,
glutathione (GSH)
10 mM

18

. The normal intracellular concentration of GSH ranges from 5 to

19

, therefore the binding of platinum-containing drugs to GSH is highly probable.

Cells with elevated glutathione (>10mM) are more resistant to cisplatin

20

, indicating its

clinical importance. Due to these metabolic consequences resulting in low cellular PtDNA binding, it is necessary to fully investigate the interactions of sulfur-containing
biomolecules with current clinical and pre-clinical platinum chemotherapeutics.
Polynuclear platinum compounds are a structurally discrete class of drugs whose
chemical and biological properties differ significantly from cisplatin. 21-23 BBR3464, the
only non-cisplatin-like molecule to enter human clinical trials, and has promising activity
in cisplatin-resistant, cisplatin-sensitive and p53 mutant tumors.24-26 BBR3464 is also
forty to eighty fold more potent on a molar basis than cisplatin. 27 Promising pre-clinical,
Phase I and Phase II clinical studies of BBR3464 have been offset to some extent by
rapid degradation of BBR3464 into inactive metabolites due to enhanced interactions
with plasma proteins.28-29 The production of these inactive metabolites may be
replicated by the chemical reactions of BBR3464 with reduced GSH. 18 These
pharmacokinetic factors are thought to contribute to reduced activity in gastric and lung
cell carcinomas

30-31

.

For the development of subsequent generations of platinum

derivatives, it is necessary to design platinum compounds which may have the ability to
avoid or minimize these metabolic deactivations.
Most platinum chemotherapeutics bind to DNA in a covalent manner by formation
of a Pt-DNA adduct. Replacement of the chloride leaving groups of BBR3464 with
substitutionally „inert‟ ammine ligands or „dangling‟ ammines, H 2N(CH2)6NH3+, gives
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„non-covalent‟ polynuclear platinum compounds; most notably TriplatinNC, Figure 4.1.
Although chemically non-reactive, TriplatinNC binds to DNA through the formation of a
„phosphate clamp‟, a ligand mode of binding distinct from the “classical” minor-groove
binders and intercalators.32 TriplatinNC has significantly higher cellular accumulation
than either BBR3464 or cisplatin, and in some cases equivalent or greater cytotoxicity
than cisplatin.33-34
Biophysical studies on the interaction of TriplatinNC with albumin have shown the
presence of an initial, electrostatic, association with the protein. 35 Previous studies
have shown that the interactions of cationic lipids with albumin give approximate binding
ratios of 1-2:1 (Lipid:Albumin).36 Due to its‟ high charge, TriplatinNC would be expected
to associate to albumin and other serum proteins in vivo, but in the absence of a
substitution-labile leaving group, would not be expected to undergo the same types of
deactivation reactions as seen with the covalent platinum analogs.

12,17,35

This protein

association, in the absence of deactivation, could provide a promising and novel
pharmacokinetic profile not seen in current clinical platinum regiments. This paper
addresses the effects of serum protein and glutathione deactivation on platinum drug
trafficking and the consequences for compound efficacy, levels of cellular accumulation,
DNA adduct formation, and intracellular distribution. The effects of protein association
on intracellular localization were examined by confocal microscopy using a new,
versatile fluorophore for platinum drugs based on 7-nitro-2,1,3-benzoxadiazole (NBD).

Results and Discussion
Importance of Glutathione in TriplatinNC Mediated Cytotoxicity
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One of the main intracellular biomolecules is glutathione (GSH), which has an
important role in determination of cellular sensitivity to cytotoxic drugs. (Figure 4.1A)
The cellular glutathione level in HCT116 cells was decreased using buthionine
sulphoximine (BSO), which inhibits gamma glutamylcysteine synthetase, a rate limiting
enzyme in glutathione synthesis.37-38 As the cellular glutathione level was reduced,
cisplatin, and BBR3464-induced apoptosis was augmented, demonstrating their
interactions with glutathione. After 48 hours of treatment, BSO alone and BBR3464induced apoptosis were 1% and 18% (as in control sample), but the combination of
BBR3464 and BSO increased apoptosis to 58% (Figure 4.1B). The results showed
consistency in testing with cisplatin. BSO increased cisplatin-induced apoptosis from
14% to 45% (Figure 4.1B). In striking contrast to these covalent Pt drugs, TriplatinNCinduced cytotoxicity was completely unaltered by inhibiting glutathione synthesis.
(Figure 4.1B)
Since some efflux mechanisms have been shown to be dependent on glutathione
39

, the effects of BSO on the cellular accumulation of platinum drugs was measured.

Cellular platinum levels were measured via ICP-OES in cells treated with platinum
drugs +/- BSO to determine if the increase observed in cytotoxicity is the result of
enhanced cellular uptake of platinum drugs. As shown in Figure 4.1C, BSO did not
influence cisplatin, BBR3464, or TriplatinNC cellular accumulation. Hence, cellular
accumulation does not play a role in the augmentation of Pt-induced cytotoxicity by
BSO.
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Figure 4.1 (A) Chemical structures of cisplatin (top), BBR3464 (middle) and TriplatinNC (bottom). (B)
Effect of BSO on platinum drug-induced cytotoxicity in HCT116 cells. Sub-diploid cell content was
detected by PI-DNA staining. HCT116 cells were cultured with 10µM cisplatin, 50µM BBR3464,, or 40µM
TriplatinNC for 48h in the absence or presence BSO. Drugs were added to the media after 1h of
treatment with BSO. (C) Effect of BSO on platinum drug cellular uptake in HCT116 carcinoma cell lines.
HCT116 cells were cultured with 20µM cisplatin for 16h, 20µM BBR3464 for 8h, or 20µM TriplatinNC for
3h in the absence or presence of 500µM BSO. Drugs were added to the media after 1h of treatment with
BSO. Each point represents the average (+/- SEM) of three independent experiments.
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Effects of Protein Binding on Cisplatin, BBR3464, and TriplatinNC
The pharmacokinetic profiles in Phase I clinical trials of BBR3464 and cisplatin
have been shown to be vastly different, with protein binding in BBR3464 being much
higher than cisplatin at early time points.27 To evaluate the effect of protein binding on
drug deactivation, cisplatin, BBR3464 and TriplatinNC were incubated with human
plasma or human serum albumin for selected time points. Analysis of platinum content
by ICP-OES shows an increase in protein binding over time for both cisplatin and
BBR3464 after incubation with whole serum. This time dependent increase in protein
binding represents a displacement of the platinum-chloride bond and the formation of
the covalent platinum-protein adduct. (Figure 4.2) In contrast, with the non-covalent
compound, TriplatinNC, a 1:1 drug protein complex is immediately formed, representing
a rapid association of the positively charged drug, presumably with negative regions of
serum proteins.(Figure 4.2) Due to the chemical nature of TriplatinNC, the initial noncovalent binding is not followed by covalent drug–protein adduct formation.
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Figure 4.2 Effects of protein binding on free drug availability of cisplatin, BBR3464, TriplatinNC. Final
binding ratio of platinum compounds to human plasma over time.
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Role of Protein Binding on Cytotoxicity of Cisplatin, BBR3464, and TriplatinNC
In theory, once a covalent platinum-protein adduct is formed, the drug “loses” its
cytotoxic effect and is rendered inactive.40 To further understand the differences in
binding profile between covalent and „non-covalent‟ platinum compounds with HSA,
cytotoxicity assays were performed on the protein bound derivatives of cisplatin,
BBR3464, and TriplatinNC (cisplatin/HSA, BBR3464/HSA, and TriplatinNC/HSA) and
compared to the free drug IC50 values in A2780 ovarian carcinoma cell lines. As seen in
Figure 4.3A, A2780 cells treated with cisplatin/HSA show a large decrease in drug
efficacy as compared with treatment of cisplatin alone. The same trend can be seen
with BBR3464/HSA and BBR3464. (Figure 4.3B) In stark contrast, A2780 cells showed
no change in growth inhibition when treated with the complex TriplatinNC/HSA
(IC50≈3µM) as compared to treatment of the drug alone, TriplatinNC (IC 50≈3µM). (Figure
4.3C)
Incubation of cisplatin, BBR34364 and TriplatinNC with whole serum provides a
physiological approach to studying the effects of protein binding on drug efficacy.
Cisplatin and BBR3464 both show a time-dependent decrease in cytotoxicity upon
incubation followed by cellular exposure after pretreatment with serum. (Figure 4.3 D,
E) For cisplatin and BBR3464, the observed IC50 values decreased from 0.6µM to
>30µM, and 0.2µM to >30µM respectively over a 72 hour period. Cellular treatment with
TriplatinNC after 72hr media incubation showed no marked decrease in IC 50 value,
remaining approximately 3µM at all timepoints. (Figure 4.3F).
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Figure 4.3 Influence of protein binding on platinum drug efficacy in A2780 ovarian carcinoma cells. (A)
Cisplatin cytotoxicity (▲) in A2780 cells compared with the treatment of cisplatin/HSA (■). (B) BBR3464
cytotoxicity (▲) compared with the treatment of BBR3464/HSA (■). (C) TriplatinNC cytotoxicity (▲)
compared with the treatment of TriplatinNC/HSA (■). (D-F) Platinum compounds were incubated with
serum supplemented media for 0-72hrs. Cellular grown inhibition was then measured after treatment.
Efficacy of cisplatin (D), BBR3464 (E), and TriplatinNC (F) following increased serum incubation times (072hrs). A2780 cells were cultured in the indicated concentrations of each compound for 72h. Percent
growth inhibition was determined by comparing live cell numbers in treated and untreated cultures after
72h, as measured by MTT. Values are the average (+/- S.E.M.) of three independent experiments.
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Effects of Protein Binding on Cellular Drug Accumulation
Since the rate of cellular uptake and total accumulation correlates to the cytotoxic
effect of platinum drugs, cellular accumulation of each platinum compound and its
protein bound derivative was examined at IC90 concentrations, Figure 4.4. Treatment of
A2780 cells with cisplatin produced an increase in cellular platinum levels in a time
dependent manner, reaching approximately 30 attomole Pt/cell after 24hrs. In contrast,
cells treated with cisplatin/HSA showed a drug accumulation of 5 attomole Pt/cell or less
at all time points. (Figure 4.4A) Cellular treatment with BBR3464 also shows a time
dependent increase in drug concentration, reaching approximately 100 attomole Pt/cell
after 24hrs. (Figure 4.4B) In contrast to cisplatin/HSA, the protein bound derivative of
BBR3464 shows a sporadic increase in platinum concentration over time. Although
BBR3464 is covalently bound to albumin, the chemical nature of this binding may cause
the tri-nuclear drug to degrade into di-nuclear and mononuclear non-covalent, noncytotoxic metabolites as seen previously with the treatment of blood cells with
BBR3464.

18,29,41

It is reasonable to assume that these di-nuclear and mononuclear

metabolites may also enter cells and contribute to the measurement of Pt levels. In
contrast, platinum accumulation in cells treated with TriplatinNC and TriplatinNC-HSA
was nearly identical at all time points, reaching approximately 400 attomole Pt/cell at the
24hr timepoint. (Figure 4.4C) Note again the enhanced accumulation of charged
trinuclear drugs in comparison to cisplatin.
To examine the role of whole serum deactivation on the rate of cellular
accumulation levels for cisplatin, BBR3464 and TriplatinNC, intracellular platinum levels
were determined after 24 hours of drug exposure, following specified serum incubation
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times. Treatment of cisplatin with serum supplemented media shows a time-dependent
decrease in cellular platinum uptake following drug exposure for 24 hours. (Figure 4.4D)
Treatment of BBR3464 with serum supplemented media shows a constant level of
cellular platinum uptake following drug exposure for 24 hours. This platinum
accumulation is interpreted to correspond to a mixture of the covalent and non-covalent
metabolites of BBR3464, consistent with the metabolic degradation seen after protein
binding. (Figure 4.4E) Upon incubation with serum for 24, 48, and 72 hours and
subsequent cellular treatment, TriplatinNC cellular accumulation levels remains
constant. (Figure 4.4F) A constant IC50 value over time and a consistent rate of cellular
drug accumulation shows the ability of TriplatinNC to “by-pass” the typical protein
deactivation pathway seen with current platinum chemotherapeutics.
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Figure 4.4 Influence of protein binding on platinum cellular uptake in A2780 ovarian carcinoma cells.
A2780 Cells were treated with IC90 concentrations of cisplatin and cisplatin/HSA (A), BBR3464 and
BBR3464/HSA (B), TriplatinNC and TriplatinNC/HSA (C) for 0, 3, 6, 12, and 24 hours. For serum
incubation studies each platinum drug was pre-incubated with serum for (0-72hrs). A2780 cells were
then treated with IC90 concentrations of each compound ((D) Cisplatin, (E) BBR3464, (F) TriplatinNC) for
24hrs. After appropriate incubation times, cells were removed from the plate and washed with PBS.
Analysis of platinum content was performed on a Varian ICP-MS. Values are the average (+/- S.E.M.) of
three independent experiments.
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Effects of Protein Binding on Levels of DNA Platination
The cytotoxicity of platinum chemotherapeutics is mainly accepted to be
modulated by the frequency and type of platinum-DNA adducts formed during drug
treatment. To examine the role of protein binding on the amount of DNA platination,
A2780 cells were treated for 24hrs with IC90 concentrations of cisplatin, cisplatin/HSA,
BBR3464, and BBR3464/HSA. DNA platination levels after 24 hours of continuous
cisplatin treatment reached approximately 225 nmole Pt/g DNA, while platinum levels of
cisplatin/HSA remained less than 10 nmole Pt/g DNA. (Figure 4.5A) The same trend in
DNA adduct formation was seen with BBR3464 and BBR3464/HSA, with platinum
levels reaching 425 and 20 nmole Pt/g DNA respectively. (Figure 4.5B)
DNA platination levels of cisplatin and BBR3464 were also monitored following
serum incubation.

After incubation with serum proteins for 24, 48, and72hrs, both

cisplatin and BBR3464 DNA platination levels were reduced.

Initial levels of DNA

platination for cisplatin were approximately 225 nmol platinum / g DNA. After 72hrs of
serum treatment prior to cell treatment, DNA platination levels were reduced to 31 nmol
platinum / g DNA. (Figure 4.5C) The same trend was seen with serum pre-treatment of
BBR3464, where platinum levels decrease from 425 nmol platinum / g DNA to 230 nmol
platinum / g DNA. (Figure 4.5D) The decreases in DNA platination seen after protein
binding are directly responsible for the reduced activity of both cisplatin and BBR3464.
Due to the non-covalent nature of TriplatinNC-DNA binding 32, isolation of cellular
DNA may disrupt the interaction. To resolve this inherent problem, we have developed a
new fluorescent probe for platinum and used fluorescence microscopy as a tool to
examine the effects of protein binding on cellular distribution and DNA platination.
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Figure 4.5 Influence of protein binding on DNA platination in A2780 ovarian carcinoma cells. A2780 Cells
were treated with IC90 concentrations of cisplatin and cisplatin/HSA (A), BBR3464 and BBR3464/HSA for
24 hours. For serum incubation studies each platinum drug was pre-incubated with serum for (0-72hrs).
A2780 cells were then treated with IC90 concentrations of each compound ((C) Cisplatin, (D) BBR3464)
for 24hrs. After appropriate incubation times, cells were removed from the plate and washed with PBS.
Cellular DNA was then extracted and analysis of platinum content was performed on a Varian ICP-MS.
Values are the average (+/- S.E.M.) of three independent experiments.
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Fluorescent Drug Design of TriplatinNC-NBD and Cisplatin-NBD
The use of molecular imaging techniques, such as confocal microscopy, is an
important tool in the understanding of platinum drug trafficking and intracellular
distribution. To utilize this approach, new fluorescent platinum derivatives were
developed using NBD fluorophores. Hambley has summarized recent fluorescent
approaches to monitoring platinum trafficking.42 The advantage of the NBD approach is
that rather than use chelates like ethyelenediamine and cumbersome chemical
modifications, the NBD addition is performed on a primary amine and gives analogs
very similar to the “parent drugs”. Previous attempts at “tagging” platinum compounds
have yielded cisplatin derivatives in which FITC and Alexa based fluorophores have
been utilized. These derivatives tend to mimic the biological properties of the
fluorescent “tag” rather than the platinum moiety itself.

42

In the case of TriplatinNC, we

conjugated the NBD fluorophore directly to the primary amine on each end of the
complex, and for cisplatin, we replace the existing amine group with NBD-ethane-1,2diamine. TriplatinNC-NBD shows only a 12% increase in molecular weight, retains a
high positive charge (6+), and shows similar cytotoxicity to TriplatinNC. (Figure 4.6A)
Cisplatin-NBD has a molecular weight increase of 66%, substantially less than seen
with FDDP 42, and also retains a cytotoxic profile in A2780 cells. (Figure 4.6B)

Role of Albumin in the Cellular Localization of Cisplatin and TriplatinNC
The mechanisms of cellular uptake and distribution of albumin and other serum
proteins have been extensively studied and show that serum proteins localize to
lysosomal regions of the cytosol.43 The use of a non-covalent drug, TriplatinNC, affords
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a unique handle to examine how macromolecule association affects small platinum
molecule biodistribution – in the absence of platinum bond-forming reactions. Confocal
microscopy was therefore employed to investigate how internalization and localization
of cisplatin and TriplatinNC is affected by albumin.

A2780 cells were treated with

cisplatin-NBD (15µM) and cisplatin-NBD/HSA (1mg/mL) to investigate the role of
covalent protein binding on drug localization. LysoTracker® Red was used as a
lysosomal marker to indicate uptake of HSA. (Figure 4.7) Cisplatin-NBD was shown to
localize throughout the cytosol and, to a lesser extent, the nucleus. (Figure 4.8A) This
distribution is consisted with the fact that less than 10% of cellular cisplatin is found in
the nucleus. After treatment of cisplatin-NBD/HSA, the cytosolic and nuclear localization
was significantly reduced and limited to lysosomal regions of the cytosol. Co-localization
of cisplatin-NBD/HSA and LysoTracker® Red was seen at a greater extent than with the
treatment of cisplatin alone, indicating an increase in drug deactivation after protein
binding.
HSA (1mg/mL) and TriplatinNC-NBD (15µM) (Protein:Drug, 1:1) were preincubated in serum-free media for 2hrs to ensure complex formation. Upon treatment
with TriplatinNC-NBD/HSA for 6hrs, punctate cellular localization of LysoTracker® Red
was observed in a pattern consistent with lysosomal accumulation while TriplatinNC
was shown to localize throughout the cytosol and nucleolus. The uptake of TriplatinNCNBD alone was shown to be identical to the localization seen upon treatment of the
protein bound complex. (Figure 4.8B) The difference in accumulation patterns between
TriplatinNC and LysoTracker® Red, and more importantly, the similarity between
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TriplatinNC-NBD and TriplatinNC-NBD/HSA localization, show the ability of TriplatinNC
to avoid metabolic deactivation associated with serum binding.

106

Figure 4.6 MTT cytotoxicity assay of fluorescent platinum derivatives, TriplatinNC and TriplatinNC-NBD
(A) and cisplatin and cisplatin-NBD (B)
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Figure 4.7 Confocal laser scanning micrographs of A2780 cells. After incubation with FITC-albumin
®
o
(1mg/mL) for 1hr and with LysoTracker Red (75 nM) for 30 min at 37 C, cells were fixed and observed
®
by confocal laser scanning microscopy. (left) LysoTracker Red (red) + DAPI (blue) (B) FITC-albumin
(green), (C) merged (A+B). A2780 Cells were grown on 4-well chamber slides (Lab-TekII Chamber Slide)
for 2-3 days until cells reached near-confluency. Cells were then incubated with FITC-albumin (1 mg/mL)
®
o
for 60 min, and with LysoTracker Red (75 nM) for 30 min at 37 C. After treatment, slides were washed
3x with ice-cold PBS and fixed with 3% paraformaldehyde. Paraformaldehyde was removed and cells
were washed again with 3x PBS and allowed to dry. Slides were then mounted with Vectashield
mounting media containing DAPI. Fluorescence was observed by confocal laser scanning microscopy
(Zeiss LSM 510).
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Figure 4.8 Role of protein binding on the cellular localization and distribution of cisplatin and TriplatinNC.
Confocal laser scanning micrographs (A-B) of A2780 cells. (A) (top row) Cisplatin-NBD (15uM) (green)
®
incubated with A2780 cells for 24hrs and LysoTracker Red (75nM) (red) for final 30min of drug
incubation. (A) (bottom row) Cisplatin-NBD/HSA (1mg/mL) (green) incubated with A2780 cells for 24hrs
®
and LysoTracker Red (75nM) (red) for final 30min of drug incubation. Orange color represents areas of
drug-protein co-localization. (B) (top row) TriplatinNC-NBD (15uM) (green) incubated with A2780 cells for
®
6hrs and LysoTracker Red (75nM) (red) for final 30min of drug incubation. (B) (bottom row) TriplatinNC®
NBD/HSA (1mg/mL) (green) incubated with A2780 cells for 6hrs and LysoTracker Red (75nM) (red) for
final 30min of drug incubation. Orange color represents areas of drug-protein co-localization. Slides were
mounted with Vectashield mounting media containing DAPI (blue). Fluorescence was observed by
confocal laser scanning microscopy (Zeiss LSM 510). (C) Chemical structures of TriplatinNC-NBD (top)
and Cisplatin-NBD (bottom).
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Conclusion
This study shows, for the first time, a platinum chemotherapeutic with a
substantially enhanced and distinctly different pharmacokinetic profile than that of any
clinically developed platinum drug. This work has shown the significance of the
interaction of TriplatinNC with plasma as well as individual intracellular and extracellular
proteins.

The non-covalent binding of TriplatinNC to serum proteins allows for an

interaction with the protein, but not a deactivation of the platinum compound. The
deactivation of cisplatin and BBR3464 upon binding to glutathione, serum or albumin
show the major problems associated with the treatment of cancer using the current
platinum chemotherapeutic regiment.
The data also allows one to examine the role of albumin as a drug carrier or drug
delivery system for TriplatinNC. Albumin is known to function as an important protein in
the maintenance of osmotic pressure and also as a transport protein involved in the
distribution of hormones, fatty acids and metal ions.44-45 Once administered, TriplatinNC
would be expected to bind to plasma proteins in a non-covalent manner and then be
transported to the cellular surface or become actively transported internally through the
endocytosis of albumin.43 The mechanism of uptake of TriplatinNC and the role of
albumin in this process was examined by utilizing novel fluorescently labeled derivatives
of both cisplatin and TriplatinNC. Further, the non-covalent drug is a unique probe for
studying platinum drug molecule-biomolecule interactions in cells. TriplatinNC not only
presents a new mode of DNA binding, distinct from any clinical platinum agent, but also
allows for the elimination of covalent Pt-protein adduct formation, thus creating a novel
pharmacokinetic and cytotoxicity profile worthy of further development.

110

Materials and Methods
Materials
BBR3464, cisplatin, and TriplatinNC were synthesized according to methods reported
previously.

46-48

Synthesis of TriplatinNC-NBD and Cisplatin-NBD is described in the

methods section. Human plasma was purchased from Innovative Research Inc.
Albumin

from

human

serum,

minimum

99%,

FITC-Albumin,

and

Buthionine

sulphoximine (BSO) was obtained from Sigma-Aldrich (St. Louis, MO). LysoTracker®
Red DND-99 was obtained from Invitrogen and recombinant HSA (rHSA) was a
generous gift from Delta Biotechnologies.

Synthesis of Cisplatin-2-NBD and TriplatinNC-NBD
N-(7-nitro-2,1,3-benzoxadiazol-4-yl)hexane-1,6-diamine. Ligand was synthesized by
a modification of a described procedure.49 BOC–diaminohexane hydrochloride was
dissolved in ddH20 and NBD-Cl (5eq) and DIPEA (2eq) was added. After the mixture
had been stirred at room temperature overnight the product was extracted with diethyl
ether. The organic phase was washed with brine (4x10 mL), dried over Na 2SO4 and
purified by flash chromatography (CHCl3/EtOAc, 90:10). The BOC protecting group of
the purified intermediate was removed by using trifluoroacetic acid (1 mL) at room
temperature. After the mixture had been stirred overnight, excess TFA was evaporated,
and the oily product was treated with diethyl ether to yield the product as orange
crystals.
N-(7-nitro-2,1,3-benzoxadiazol-4-yl)ethane-1,2-diamine

(L):

BOC–diaminoethane

(0.79 ml, 4.99 mmol) was dissolved in 20 ml ethanol containing a 10% w/w of Na 2CO3,
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and NBD-Cl (0.50 g, 2.51 mmol) was added. The mixture was stirred at room
temperature overnight, then 50 ml of water were added and the product was extracted
with diethyl ether (3 x 30 ml). The organic phase was washed with brine (3 x 30 ml),
dried over Na2SO4 and purified by flash chromatography (CHCl3/EtOAc, 70:30). The
BOC protecting group of the purified intermediate was removed by using 2 ml of
trifluoroacetic acid at room temperature. After the mixture had been stirred overnight,
excess TFA was evaporated, and the oily product was treated with diethyl ether to yield
the trifluoroacetate salt as orange crystals.
Both ligands were neutralized by dissolving in a mixture of H2O/Ethanol 1:1 and addition
of 1 equivalent of NaOH. The neutral ligand was then extracted with CH2Cl2. The
organic fractions were dried over K2CO3 and the solvent removed under vacuum. The
product was dried under vacuum overnight.
TriplatinNC-NBD2: BBR3464 Cl- salt was treated with 5.97eq of AgNO3 in ddH20 and
allowed to stir at room temperature for 4hrs. AgCl was filtered off and to the clear
solution was added NBD-diaminohexane (5eq) and DIPEA (5eq). The solution was
allowed to stir at 50oC overnight. The solution was then evaporated to dryness and the
resulting orange oil was re-dissolved in ddH20 and excess NBD-diaminohexane was
removed by extraction with EtOAc (5x50 mL). The aqueous layer was removed and the
product was redissolved in ddH20 and lyophilized. The resulting orange powder was
washed with EtOAc, CHCl3 and diethyl ether to yield TriplatinNC-NBD2 (1.7mg, 30%)
1

H NMR D2O δ (ppm): 8.54 (d, 2H); 6.23 (d, 2H); 3.00 (t, 12H); 2.72 (m, 4H); 1.67 (m,

16H); 1.42 (m, 16H).
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Cis-[PtCl2((N-NBD)ethane-1,2-diamine)(NH3)]: The synthesis of this compound was
achieved by means of a modification of a patented procedure 50. K[PtCl3(NH3)] (30.0 mg,
0.084 mmol) was dissolved in 5 ml of a 15 mM aqueous solution of KCl. A solution of KI
(41 mg, 0.248 mmol) in 1 ml of water was prepared. The KI solution was added to the
K[PtCl3(NH3)] solution, followed by a slight excess of the NBD amino ligand L (20.5 mg,
0.091 mmol). The combined solution was stirred in the dark for 5 h at room temperature.
A redish precipitate formed which was collected, washed with cold water, cold
methanol, and dried under vacuum at room temperature overnight. The product was
Cis-[PtI2((N-NBD)ethane-1,2-diamine)(NH3)], confirmed by NMR. The Cis-[PtI2((NNBD)ethane-1,2-diamine)(NH3)] (40 mg, 0.067 mmol) was suspended in 2 ml of a
mixture H2O/Acetone 85:15 and 1eq of silver nitrate was added to the suspension. It
was then stirred for 24 h in the dark at room temperature. The suspension was filtered
and 200 ml of HCl (˜12 M) were added to the filtrate. The solution was stirred at room
temperature for 2 h, during which time a black precipitate formed. The precipitate was
filtered and the solution concentrated to obtain the product as a brownish powder, which
was washed with ice cold methanol, ether and dried under vacuum. 1H NMR D2O δ
(ppm): 8.45(d, 1H); 6.33 (d, 1H); 3.81 (t, 2H); 3.27 (t, 2H). ESI-MS: m/z: (M+H)+ 507.22;
(M-Cl)+ 471.23

Cell System
The colorectal carcinoma cell lines HCT116 were the kind gift of Bert Vogelstein (JohnsHopkins University, Baltimore, MD). HCT116 and A2780 cells were cultured in RPMI

113

1640 with 10% fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin in
humidified air with 5% CO2.

Human Plasma Binding
Solutions of each drug were prepared in PBS and added to human plasma such that the
final concentration of complex was 0.9mM (1:1 v/v). The reactions were incubated at
37 °C for 0, 0.5, 2 and 24 hours.

Unreacted drug was removed by centrifugation

through a Millipore Microcon YM-10 (10,000 kDa) membrane filter at 14,000xg for
30 min. The centrifuge cup was upturned in a second eppendorf and centrifuged at
1000xg for 3 min to isolate the protein-bound drug. Both ultrafiltrate and protein samples
were stored at -20°C immediately following centrifugation. The digestion procedure
followed published methods.47 Analysis of platinum content for both the protein-bound
and unreacted samples was performed on a Varian ICP-OES. Protein concentration
was determined by the Bradford method with human serum albumin as the standard. 51

Formation of Drug-Albumin Complex
Platinum compounds (Cisplatin, Cisplatin-NBD, BBR3464, and TriplatinNC) were
incubated with HSA for 72hrs at 10:1(Drug:Protein). Non-protein bound drug was
removed by centrifugation using method described above. The protein was collected,
redissolved in 5mL PBS and immediately frozen at -20oC.

Pt concentration was

determined using ICP-OES by removing a small aliquot of the Pt-protein solution before
freezing. Protein concentration was determined by the Bradford method with human
serum albumin as the standard.51
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BSO Treatement, Propidium Iodide DNA Staining, and Analysis of Apoptosis
HCT116 cells were cultured in 6-well plates at an initial density of 7.0 × 10 4 cells/ml.
Different concentrations of drugs were added to each well as indicated.

Total cell

contents (apoptotic and viable cells) were collected. In experiments using BSO, Pt drug
concentrations were adjusted to achieve approximately 15%-20% apoptosis, allowing
us to measure enhancement or inhibition. Samples were fixed in an ethanol and fetal
bovine serum solution, washed with PBS, and stained with a solution of propidium
iodide (PI) and RNase A, as described previously

52

. Samples were then analyzed for

subdiploid DNA content on a Becton Dickinson FACScan flow cytometer (BD
Biosciences, San Jose, CA). It is noteworthy that this protocol differs significantly from
the more common PI-based exclusion, which only differentiates live versus dead cells.
Through fixation and RNase A treatment, we were able to detect intact versus
fragmented DNA, revealing discrete stages of the cell cycle and the percentage of the
population undergoing apoptosis.

Cellular Growth Inhibition
The MTT assay was used to determine growth inhibition potency of platinum drugs and
the corresponding protein bound derivatives.53 A2780 cells were seeded in 96-well
plates at 6,500 cells/well in 200μL of RPMI 1640 media and allowed to attach overnight.
Media was removed and 200µL of each compound was added after serial dilution in
quadruplicate wells and exposed to cells for 72h. For time dependent media incubation
studies 500µM of each Pt compound was incubated in RPMI 1640 media supplemented
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with 10% FBS (1:1 v/v) for 0, 24, 48, and 72hrs before cellular treatment. Samples
were diluted to treatment concentrations [30µM – 0.25µM] with fresh media after
appropriate time points and cells were treated accordingly. Plates were then washed
with PBS and 100µL of 5mg/mL MTT solution was added. MTT solution was incubated
with cells for 3h at 37oC. After incubation, MTT solution was removed and 100µL of
DMSO was added. Quantification of cell growth in treated and control wells was then
assessed by measurement of absorbance at 562nm. IC 50 values were determined
graphically.

Cellular Uptake of Drug and Drug-HSA Complexes
A2780 cells were plated in 10cm dishes at 2 million cells/dish and allowed to attach
overnight. Cells were then treated with IC90 concentrations of each drug and drug-HSA
complex,15 μM for TriplatinNC, 4µM for Cisplatin, and 2.5µM for BBR3464, in 15mL
media for 0, 3, 6, 12, and 24 hours. After appropriate incubation times, cells were
removed from the dish with trypsin and centrifuged for 5min at 1000xg. Media was
removed, cell pellet was washed three times with PBS, cells were counted and
resuspended in 250μL of ddH20.

Samples were then digested following published

methods.47 Analysis of Pt content was performed on a Varian ICP-MS. Standards and
blank were prepared similarly.

Quantification of DNA-Drug Adducts
A2780 cells were plated in 10cm dishes at 2 million cells/dish and allowed to attach
overnight. Cells were then treated with IC90 concentrations of each drug and drug-HSA

116

complex, 4µM for Cisplatin, and 2.5µM for BBR3464, in 15mL media for 24 hours. For
time dependent media incubation studies 500µM of each Pt compound was incubated in
RPMI 1640 media supplemented with 10% FBS (1:1 v/v) for 0, 24, 48, and 72hrs before
cellular treatment. After incubation, cells were removed from the dish with trypsin and
centrifuged for 5min @ 1000xg. Media was removed and cell pellet was washed three
times with PBS and suspended in 200μL of ddH20. DNA was extracted using a DNeasy
blood and tissue kit (Qiagen) according to the manufacturer‟s protocol. Extent of DNA
platination was measured on a Varian ICP-MS.

Confocal Laser Scanning Microscopy of A2780 Cells
A2780 Cells were grown on 8-well chamber slides (Lab-TekII Chamber Slide) for 2-3
days until cells reached near-confluency. A2780 cells were treated with cisplatin-NBD
(15µM) and cisplatin-NBD/HSA (1mg/mL) for 24hrs. LysoTracker® Red (75nM) was
added to the slide for the final 30 minutes of drug treatment time. For TriplatinNC-NBD
(15µM) and TriplatinNC-NBD/HSA (1mg/mL), and FITC-Albumin (1mg/mL), A2780 cells
were treated for 6hrs and LysoTracker® Red (75nM) was added to the slide for the final
30 minutes of drug treatment time. After treatment, slides were washed 3x with ice-cold
PBS and fixed with 3% paraformaldehyde. Paraformaldehyde was removed and cells
were washed again with 3x PBS and allowed to dry. Slides were then mounted with
Vectashield mounting media containing DAPI. Fluorescence was observed by confocal
laser scanning microscopy (Zeiss LSM 510).
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Chapter 5: Design, Synthesis, and Anticancer Activity of FluorescentBased Dual Function trans-Platinum-NBD Complexes

Brad T. Benedetti, Alberto Martinez, and Nicholas P. Farrell*
Department of Chemistry and Massey Cancer Center
Virginia Commonwealth University, Richmond, Virginia. USA
Synthesis and Fluorescence Titration Experiments performed by Dr. Alberto Martinez

Introduction
Platinum drugs continue playing a prominent role in the treatment of cancer and
are administered in around 50% of diagnosed patients.1-3 Cisplatin remains the most
used inorganic antitumor drug to date. The cytotoxicity of cisplatin is accepted to result
mainly from the formation of bifunctional 1,2-intrastrand DNA crosslinks with purine
bases, resulting in the inhibition of DNA synthesis and replication. 4 Unfortunately the
success of cisplatin based chemotherapeutics is limited due to eventual acquired drug
resistance and a limited range of tumor types that are treatable with the current regime.
Therefore, the present research motivation is to find new platinum based drugs which
exert a uniquely distinct mode of DNA binding.
Although the trans isomer of cisplatin, transplatin, remains clinically inactive,
platinum compounds possessing a trans geometry became a new alternative when
Farrell et al. reported the first examples of trans compounds with a higher potency than
the respective cis isomers.5-7 It is now well established that the substitution in the
inactive transplatin of one NH3 group by different families of amines, „activates‟ these
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compounds, producing cytotoxicity values higher than their cis counterparts and, in
many cases, equivalent to that of cisplatin.5-6 Two of the most common strategies in the
synthesis of such compounds are the replacement of one NH3 by a planar ligand,
typically a heterocyclic amine or aliphatic primary amine. Because the structure of the
DNA adducts determines repair, protein recognition and other crucial cellular processes,
it is widely accepted that the distinct platinum-DNA adducts that are formed when trans
compounds interact with DNA are key for their potential therapeutic effectiveness. One
possible explanation for the cytotoxic activity, especially for trans-platinum compounds
containing heterocyclic derivatives, is the enhanced intercalation or pi-stacking seen
between nucleobases on DNA and the aromatic heterocyclic amines on the platinum
compound. This interaction provides for a pseudo bi-functional adduct, similar to the
cisplatin-DNA adducts.5
The idea of a platinum compound that possesses a dual-mode of DNA binding
has been slightly explored through the use of DNA intercalators conjugated to
cisplatin.8-10 Although somewhat successful, the design of these compounds has relied
on the use aromatic intercalators such as anthraquinone and other cytotoxic aromatic
moieties.11 After conjugation to platinum, these compounds show cytotoxicity profiles
nearly identical to that of the intercalator and therefore provide no clinical benefit over
the use of the intercalator alone. The synthetic possibilities offered by platinum
complexes allow the incorporation of not only DNA intercalators, but also different
fluorophore groups that can be used for imaging studies to gain understanding and
knowledge of the cellular distribution and action of these drugs. This strategy is a
relatively non-invasive procedure that has been successfully exploited in the case of
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several cisplatin-like compounds,12-13 but with very little research devoted to transplatinum complexes. By employing the use of both a fluorescent probe and a DNA
intercalator conjugated to a platinum compound, cellular imaging studies can be
incorporated to aid in the understanding of drug action.
In this work we report the anticancer activity and primary insights into the
mechanism of action of a series of novel water-soluble trans-platinum complexes
(Figure 5.1) that incorporate an amino ligand composed of an aliphatic carbon chain
and

a

planar

fluorophore

intercalator,

NBD

(4-Chloro-7-nitrobenzofurazan).

Interestingly, all three compounds are composed of individual components that are
inactive when used separately. We also report for the first time the imaging of cellular
processing of a trans-platin analogue by means of fluorescence microscopy. This is
especially significant due to the antitumor potency the compounds exhibit when
compared to cisplatin.
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Figure 5.1 General Chemical Structure of Trans-NBD Compounds
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Results and Discussion
It is well known that platinum compounds, including those with trans geometry,
target DNA and form bifunctional adducts by covalently binding with guanine and
adenine nucleobases. The intra- or inter-strand nature of the adducts formed strongly
depends on the nature of the complex.2,14-16 The rationale for the choice of NBD as
fluorophore is in addition justified by its ability to intercalate between the nucleobases of
DNA, a consequence of its high similarity with adenine.17 This fact, therefore, allows all
compounds the potential capability of a dual mode of action in which the platinum atom
interacts covalently with the nucleobases while the NBD moiety intercalates with DNA.
This strategy has been used by several groups,18 but we now include an aliphatic chain
between the platinum atom and the intercalator that will allow for the modulation of the
lipophilicity/hydrophilicity of the drug and also make the compound flexible enough to
allow the NBD molecule to properly intercalate in between the “preferred” nucleobases.

DNA Intercalation of Trans-NBD Compounds
A key factor in the design of the Trans-NBD series that should drastically
influence the cytotoxic behavior is the ability of the NBD moiety to intercalate strongly
with DNA and therefore allow for the formation of uniquely distinct DNA-platinum
adducts. The un-conjugated NBD moiety has previously been shown to intercalate
between nucleobases of DNA.17

Therefore it was necessary to understand the

influence of a platinum center on its ability to bind DNA.

NBD displays a strong

emission transition in the range between 530 and 550 nm that is quenched by the
addition of a solution of DNA, indicating that intercalation of the NBD fluorophore with
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adjacent DNA nucleotides. The results can be cast in the shape of the Scatchard
equation and the strength of the intercalation can be efficiently quantified and compared
to that of the known interacalator, ethidium bromide (Table 5.1).
Ethidium bromide is a cationic dye that is widely used as a probe for native DNA.
The ethidium ion displays a dramatic increase in fluorescence when it intercalates into
DNA.19 As seen in Table 5.1, all Trans-NBD complexes show a decrease in
fluorescence when titrated against DNA, indicating the intercalation of the NBD moiety
between adjacent DNA nucleobases. The binding strength is similar in all compounds
and ligands, and is shown to be stronger than that of ethidium bromide. This fact
reinforces the proposed design of the Trans-NBD series and provides for a secondary
binding mode in addition to the classical covalent platinum-DNA interaction. The
covalent-intercalation, “dual” mode of binding, along with the addition of a “flexible”
carbon chain allows the NBD moiety to intercalate between the preferred nucleobases
as well as allowing for the modulation of the lipophilicity of the drug.
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Table 5.1 Binding affinities calculated by fluorometric titration using the Scatchard equation for interaction
of small molecules with biomolecules. Excitation and emission set at 465 and 535 nm for 2NBD and
Trans2NBD; 480 nm and 542 nm for 4NBD and Trans4NBD; 485 nm and 550 nm for 6NBD and
Trans6NBD.
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Cytotoxicity of Trans-NBD Compounds
To evaluate the role of both the NBD intercalator and the trans-platinum moiety
on the cytotoxicity of each compound, IC50 values for all three Trans-NBD compounds
and linkers (platinum-free primary amine ligand with the NBD moiety) was determined in
four tumor cell lines. Table 5.2 All complexes are significantly more cytotoxic than the
NBD-linker alone. In addition, transplatin is known to be inactive in all four cell lines at
similar concentrations.20 Therefore the increased activity observed is a consequence of
the combination of both the platinum center and NBD moiety, resulting in a “synergistic”
effect of combining both inactive components. Trans4-NBD and Trans6-NBD are more
than twice as potent as cisplatin in the A2780 ovarian cell line and, the less sensitive,
HCT116 colorectal carcinoma cell line, while both display analogous behavior in PC3
and MDA cell lines. On the other hand, Trans2-NBD shows a similar or lower profile of
activity than cisplatin in all four cell lines (Table 5.2). The use of a longer aliphatic chain,
as in Trans4-NBD and Trans6-NBD should allow for greater flexibility and in turn create
the potential for both intercalation and covalent platinum-DNA adduct formation. Steric
effects of the short two carbon chain likely also play a role in limiting the dual mode of
binding. Interesting to note, the Trans-NBD compounds show a greater cytotoxicity
profile than the published cisplatin-NBD, the cis analogue to Trans2-NBD.21 This is
probably due to the decreased water solubility of the cis derivative, resulting in a drastic
decrease in cellular accumulation and DNA platination.
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Table 5.2 Cytotoxic activity of the Trans-NBD complexes and linkers against A2780 (ovarian cancer cell
line), HCT116 (colorectal carcinoma cell line), PC3 (prostate cancer cell line) and MDA-MB-435 (breast
adenocarcinoma cell line).
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Cellular Accumulation and DNA Adduct Formation of Trans-NBD Compounds
Since the cellular accumulation and frequency of DNA adduct formation correlate
with the cytotoxic effect of most platinum compounds, the level of cellular uptake and
DNA platination of the Trans-NBD series was studied after 24 hour treatment with 10
µM of each drug. All three Trans-NBD complexes accumulate in a similar extent to
cisplatin in the HCT116 cell line, while only Trans6-NBD has a better influx/efflux ratio
than cisplatin in the A2780 cell line (Table 5.3). However, none of the Trans-NBD
complexes reach DNA more effectively than cisplatin (Table 5.3). Assuming that DNA is
the biological target for the activity of these compounds, it is clear that the different type
of adducts formed after DNA binding and intercalation result in the formation of lesions
than are more toxic than traditional bifunctional 1,2-intrastrand DNA crosslinks formed
by cisplatin. It is highly likely that these more toxic crosslinks are triggering cell signaling
pathways after platination and different repair mechanisms that are crucial for the
overall cytotoxicity of the drugs. More interesting is the comparison of cell accumulation
and DNA binding ability within the series of Trans-NBD compounds. It is clear that the
complexes that are able to accumulate within the cell and bind DNA at a higher extent
(Trans4-NBD and Trans6-NBD) and display a more cytotoxic profile in both, A2780 and
HCT116 cancer cell lines. In this sense, the lipophilicity of the drug may be playing an
important role. It is reasonable to assume that Trans4-NBD and Trans6-NBD, while both
being water soluble, will be more lipophilic than Trans2-NBD as a consequence of the
longer carbon chain attached to the NBD fluorophore, and thus more capable of
entering the cells by means of passive transport through the cell membrane.22
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Table 5.3 Cell accumulation and DNA binding for the Trans-NBD series and cisplatin in A2780 and
HCT116 cell lines. All values upon treatment with 10 µM drug after 24 hours
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Cellular Localization of Trans-NBD Compounds
Finally, knowledge of the processing and distribution of platinum drugs within
living cells is of paramount importance. Information about whether the drugs are able to
reach their intended target or if they remain in the cytosol and accumulate in other
subcellular compartments that are usually associated with drug resistance and export,
can provide insight into the differential behavior of platinum compounds. Due to the
fluorescent nature of the NBD interacalator, fluorescent confocal microscopy can be
used as a tool to examine and understand drug action and metabolism. As seen in
Figure 5.2, fluorescent microscopy images of all Trans-NBD compounds in both
HCT116 and A2780 cells, show high levels of drug localization throughout the cytosol
and to a lesser extent, inside the nucleus. This is consistent with the fact that only
about 10% of the cellular platinum reaches the nucleus of the cells. The decreased
fluorescence of the Trans-NBD compounds in the nucleus can also be explained due to
quenching upon intercalation of the NBD moiety on nuclear DNA. Increased
fluorescence is also observed in the vicinity of the nuclear membrane, likely due to drug
accumulation within the compartments of the Golgi, responsible for drug efflux and
endosome recycling.23-24 This pattern of Golgi, endosomal/lysosomal accumulation has
been noted before with various types of platinum compounds.25 The observed cell
processing of Trans2-NBD is analogous to that of Trans4-NBD, Trans6-NBD and also
for the cisplatin analogue Cisplatin-NBD,21 therefore, suggesting that the frequency and
type of DNA adduct formed play a fundamental role in the overall activity of the TransNBD series.

136

Figure 5.2 Confocal laser scanning micrographs of A2780 and HCT116 cells. After incubation with Transo
NBD compounds, 10µM for 24hrs at 37 C, cells were fixed and observed by confocal laser scanning
microscopy. (left panel) Trans-NBD compounds (green) in A2780 cells + DAPI (blue). (right panel) TransNBD compounds (green) in HCT116 cells + DAPI (blue). Cells were grown on 4-well chamber slides
(Lab-TekII Chamber Slide) for 2-3 days until cells reached near-confluency. Cells were then incubated
with 10µM of each compound for 24hrs. After treatment, slides were fixed with 3% paraformaldehyde and
mounted with Vectashield mounting media containing DAPI. Fluorescence was observed by confocal
laser scanning microscopy (Zeiss LSM 510).
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Conclusion
In conclusion, we have synthesized a new series of trans platinum compounds
more than twice as potent than cisplatin in the ovarian carcinoma cell line, A2780, and
colorectal carcinoma cell line, HCT116. The results of cell uptake and DNA binding
suggest that the higher cytotoxicity observed compared to cisplatin is not a
consequence of increased cellular accumulation, but of a different and more efficient
binding mode to DNA, due to an aliphatic amino ligand that incorporates a planar DNA
intercalator. It is believed that all complexes bind covalently the nucleobases of DNA
and intercalate between DNA base pairs through the NBD moiety. Also, the NBD-DNA
intercalations show a stronger affinity than that observed for ethidium bromide. This
dual mode of binding likely activates cell signaling pathways and therefore overcomes
cisplatin-DNA repair mechanisms. When compared within the series of Trans-NBD
complexes, there is a good correlation between, lipophilicity, cell accumulation, DNA
binding and cytotoxicity. Fluorescent microscopy shows that the complexes accumulate
preferentially in the cytosol, with areas of strong fluorescence close to the nuclear
membrane, where the lysosomes and Golgi apparatus are typically located. This dual
mode of DNA-binding, covalent and non-covalent, allow for a distinctly different
cytotoxicity profile that that of cisplatin and could allow for the development of a new
class of platinum based chemotherapeutics able to overcome current platin drug
resistance and expand the range of tumors currently treatable with clinical platinum
drugs.
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Materials and Methods
Synthesis of Ligands and Platinum Complexes
N-(7-nitro-2,1,3-benzoxadiazol-4-yl)ethane-1,2-diamine (2-NBD); N-(7-nitro-2,1,3benzoxadiazol-4-yl)buthane-1,4-diamine (4-NBD); N-(7-nitro-2,1,3-benzoxadiazol4-yl)hexane-1,6-diamine (6-NBD): BOC–diaminoethane/BOC–diaminobuthane/BOC–
diaminohexane was dissolved in ethanol containing a 10% w/w of Na2CO3, and NBD-Cl
was added. The mixture was stirred at room temperature overnight, then water was
added and the product was extracted with diethyl ether. The organic phase was washed
with brine, dried over Na2SO4 and purified by flash chromatography (CHCl3:EtOAc,
88:12 / 75:25 / 70:30 for 2-NBD, 4-NBD and 6-NBD respectively). The BOC protecting
group of the purified intermediate was removed by using trifluoroacetic acid (2 ml) at
room temperature. After the mixture had been stirred overnight, excess TFA was
evaporated, and the oily product was treated with diethyl ether to yield the
trifluoroacetate salt as orange crystals. The compound was neutralized by dissolving it
in a mixture H2O/Ethanol 1:1 and addition of 1 equivalent of NaOH. The neutral ligand
was then extracted with CH2Cl2. The organic fractions were dried over K2CO3 and the
solvent removed under vacuum. The product was dried under vacuum overnight. The
absence of TFAcetate was confirmed by 19F NMR.

Trans-[PtCl2((N-NBD)ethane-1,2-diamine)(NH3)] (Trans2-NBD): Cisplatin (26 mg,
0.087 mmol) was suspended in 5 ml of deionized water and one equivalent of AgNO 3
was added. The mixture was stirred at 45ºC for 4.5 hours, then cooled to 5ºC for 2
hours to allow full precipitation of AgCl. The silver white salt was double filtered through
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ligand was added (19.34 mg, 0.087 mmol). That solution was stirred at room
temperature overnight, then filtered. 1.5 ml of HCl 37% were added and the resulting
solution was stirred at 75ºC for 5 hours. The orange clear solution was concentrated
under vacuum until a precipitate appeared (~ 3 ml) and then cooled to 5ºC to complete
the precipitation of the final product. The orange powder was filtered, washed with icecold water, ice-cold ethanol and ether, then dried under vacuum for 24 hours. 1H NMR
D2O δ (ppm): 8.47(d, 1H); 6.35 (d, 1H); 3.82 (t, 2H); 3.28 (t, 2H).

195

Pt NMR D2O δ

(ppm): 2148(s)

Trans-[PtCl2((N-NBD)buthane-1,4-diamine)(NH3)]

(Trans4-NBD):

The

same

procedure as described for Trans2-NBD was followed. 1H NMR D2O δ (ppm): 8.36(d,
1H); 6.23 (d, 1H); 3.49 (m, 2H); 2.91 (m, 2H); 1.69 (m, 2H).

195

Pt NMR D2O δ (ppm):

2158(s)

Trans-[PtCl2((N-NBD)hexane-1,6-diamine)(NH3)] (Trans6-NBD): The same procedure
as described for Trans2-NBD was followed. 1H NMR D2O δ (ppm): 8.36(d, 1H); 6.23 (d,
1H); 3.45 (m, 2H); 2.85 (m, 2H); 1.66 (m, 2H); 1.54 (m, 2H); 1.32 (m, 2H).

195

Pt NMR

D2O δ (ppm): 2164(s). EA calculated for C12 H20 N6 O3 Pt Cl2: C, 25.63; H, 3.59; N,
14.94. Found: C, 25.63; H, 3.57; N, 14.96.

Cell System
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HCT116 and A2780 cell lines were cultured in RPMI 1640 (Invitrogen), supplemented
with 10% calf serum (Atlanta Biologicals) and 1% penicillin/streptomycin (Invitrogen).
Cells were maintained in logarithmic growth as a monolayer in T75 culture flasks at
37°C in a humidified atmosphere containing 5% CO2.

Cellular Growth Inhibition
The MTT assay was used to determine growth inhibition potency of platinum drugs.26
A2780, HCT116, PC3 and MDA-MB-435 cells were seeded in 96-well plates at 6.5k
cells/well for A2780, 5k cells/well for HCT116 and MDA-MB-435, and 10k cells/well for
PC3 and allowed to attach overnight. RPMI 1640 media was removed and 200µL of
each compound was added after serial dilution to treatment concentrations [50µM –
0.78µM] in quadruplicate wells and exposed to cells for 72h. Plates were then washed
with PBS and 100µL of 5mg/mL MTT solution was added. MTT solution was incubated
with cells for 3h at 37ºC. After incubation, MTT solution was removed and 100µL of
DMSO was added. Quantification of cell growth in treated and control wells was then
assessed by measurement of absorbance at 562nm. IC50 values were determined by
using the standard curve analysis of SigmaPlot.

Cellular Drug Accumulation and Quantification of DNA-Drug Adducts
A2780 or HCT116 cells were plated in 10cm dishes at 2 million cells/dish and allowed to
attach overnight. Cells were then treated with 10µM of each drug for 24hrs. After 24hrs,
drug solution was removed and plates were washed 3x with PBS. Cells were then
removed from the dish with trypsin and centrifuged for 5min at 1000xg. Media was
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removed, cell pellet was washed three times with PBS, cells were counted and
resuspended in 250μL of ddH20.

Samples were digested following published

methods.27 For DNA analysis experiments, DNA was extracted using a DNeasy blood
and tissue kit (Qiagen) according to the manufacturer‟s protocol. Extent of DNA
platination and cellular platinum accumulation was measured on a Varian ICP-MS.

Fluorescence Spectrophotometric Titration
Excitation and emission wavelengths were set to 465 and 535 nm for the ligand 2-NBD
and complex Trans2-NBD; to 480 nm and 542 nm for the ligand 4-NBD and the
complex Trans4-NBD and 485 nm and 550 nm for the ligand 6-NBD and the complex
Trans6-NBD. Bandwidths were set to 5 nm and 20 nm for the excitation and the
emission,

respectively.

All

fluorescence

spectra

were

measured

in

a

Cary

Spectrophotometer instrument with an arc xenon lamp. The absorption of the sample at
the wavelength of excitation was less than 0.1 in order to obviate inner filter effects. The
fluorimetric titration was carried out at room temperature. Fixed amounts (10 µl) of a
12.5 mM solution of CT DNA were added to a 0.4 µM solution of the metal complex,
both in Tris/HCl buffer (5mM Tris/HCl and 50 mM NaClO4, pH = 7.39) and emission
spectra were monitored until saturation was reached. Binding data were cast into the
form of a Scatchard plot of r/Cf vs. r using the equation r/Cf = K(n-r) for ligandmacromolecule interactions with non-cooperative binding sites28-30, where r is the
number of moles of Ru complex bound to 1 mol of CT DNA (C b/CDNA), n is the number
of equivalent binding sites, and K is the affinity of the complex for those sites. α was
calculated according to α = (Ff-F)/(Ff-Fb), where Ff and Fb are the fluorescence of the
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free and fully bound drug at the selected wavelength, and F is the fluorescence at any
given point during the titration.31 Kb is obtained from the slope of the plot.

Confocal Laser Scanning Microscopy
A2780 and HCT116 cells were grown on 8-well chamber slides (Lab-TekII Chamber
Slide) for 2-3 days until cells reached near-confluency. The cells were treated with
Trans2-NBD, Trans4-NBD, and Trans6-NBD (10µM) for 24hrs. After treatment, slides
were washed 3x with ice-cold PBS and fixed with 3% paraformaldehyde.
Paraformaldehyde was removed and cells were washed again with 3x PBS and allowed
to dry. Slides were then mounted with Vectashield mounting media containing DAPI.
Fluorescence was observed by confocal laser scanning microscopy (Zeiss LSM 510).
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Chapter 6: Conclusion

While platinum chemotherapy represents one of the most utilized forms of cancer
treatment, all current therapies have innate problems due to inherent tumor resistance
and a limited availability of susceptible tumor types. The inherent resistance of these
tumors and the toxic side effects associated with platinum chemotherapy are, in part, a
result of metabolic deactivation.

By understanding the balance between cytotoxic

activity and metabolic deactivation it may be possible to defer many of the toxic side
effects associated with chemotherapeutics, and thus provide for substantial increases in
mean tolerated dosages and increase the number of tumors treatable by platinum
drugs. Two possible ways to diminish these types of metabolic interactions have been
described in this thesis and are (1) through the use of carboxylates ligands to “fine-tune”
the reactivity of trans-platinum compounds and thus balance the cytotoxic and
pharmacokinetic profiles and (2) through the introduction of a non-covalent antitumor
agent, TriplatinNC, which not only presents a new mode of DNA binding, distinct from
any clinical platinum agent, but also allows for the elimination of covalent Pt-protein
adduct formation.
While the cis platinum geometry has yielded three clinical platinum based drugs,
the second factor in the success of any platinum chemotherapeutic is the range of
treatable tumor types over that of the current clinical regime. By extending the platinum
geometry to include trans based platinum derivatives, this work has also attempted to
create platinum compounds which are able to treat tumor types other than that of
cisplatin and other cis based compounds. By developing a series of Trans-NBD
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compounds which include a transplatinum DNA binding agent and a DNA interacalator,
we have created transplatinum based drugs which show significant improvements in
cytotoxic activity over than of cisplatin. The goal is to combine both improvements in
metabolic deactivation and novel antitumor profiles thus creating a class of compounds
which can outperform the current clinical antitumor platinum drugs and ultimately
provide for a promising outlook for the future of cancer chemotherapeutic treatments.
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Abstract
TriplatinNC is a highly positively charged, (+8) noncovalent derivative of the
phase II clinical platinum drug, BBR3464. TriplatinNC exhibits a distinct mode of high
affinity DNA interaction, increased levels of cellular accumulation, and a significant
cytotoxic profile in mastocytoma, ovarian carcinoma, and cisplatin-resistant ovarian
carcinoma cell lines. Here, it is shown, through use of fluorescent-tagging and confocal
colocalization experiments that TriplatinNC rapidly localizes to the nucleolar
compartment in HCT116 and A2780 cells. Due to its cationic nature, it was considered
that TriplatinNC likely interacts with nucleic acid components of the nucleolus, that is,
ribosomal DNA, and its transcripts.

32

P-metabolic labeling of HCT116 cells determined

that the production rate of 47S rRNA precursor transcripts is drastically reduced as an
early event after drug treatment. Subsequently, there is a marked increase in p53

150

protein at 12hrs, followed by a robust and continuous G1 arrest at 24 and 48hrs.
Morphological characteristics of the apoptotic process are apparent within 24hrs,
including: reduction in cell size, membrane blebbing, and cytosolic vacuolization.
TriplatinNC induces cleavage of mitochondrial-dependent and -independ-ent initiators of
apoptosis, procaspase-9 and -8, followed by activation of the effector procaspase-3,
and downstream target, Parp-1. Furthermore, utilizing the isogenic HCT116 p53+/+ and
p53-/- cell lines, it was determined that these processes, are not dependent upon the
presence of p53 protein.

Introduction
The increased proliferative rate of cancer cells relies on a concomitant
upregulation of ribosomal biogenesis in order to meet the cellular demands for protein
synthesis

1-4

. The biogenesis of ribosomes is a coordinated process that largely takes

place in the nucleolar compartment of the cell. The nucleolus is formed around tandem
arrays of more than 400 copies of ribosomal RNA (rRNA) genes as they are
transcribed, processed, and assembled into ribosomal subunits 5. Recently, rRNA
synthesis has emerged as a shared target of many anticancer agents 6. The platinumbased drugs, oxaliplatin, and to a lesser extent, cisplatin, inhibit the transcriptional rate
of the 47S rRNA precursor transcript, while the antimetabolite, 5-fluorouracil (5-FU),
disrupts processing of the precursor into mature 28S, 18S, and 5.8S rRNA transcripts.
In each case, the effects are surprisingly early events; observed within hours after cell
treatment. This implies that inhibition of rRNA processes may be an early determinant of
the antiproliferative activity of these drugs. Of course, the effects of oxaliplatin, cisplatin,
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and 5-FU are not limited to rRNA processes. They are nonselective, genotoxic drugs
that modify, or incorporate into the total pool of nucleic acid

7-9

. Limiting genotoxic

events by drug-targeting only nucleic acid within the nucleolus and specifically, rRNA
synthesis, is an interesting challenge for small molecule therapeutics.
Unlike the nucleus and other membrane-bound organelles, there is no evidence
of a membrane or membrane-like structure separating the nucleolus from the
surrounding nucleoplasm. In theory, any soluble molecule could diffuse in and out of the
nucleolar compartment.

Because of sequence similarities in nuclear and nucleolar

localization signals, it is currently accepted that targeting of a specific molecule to the
nucleolus results from its direct or indirect interaction with components of the nucleolus,
that is, ribosomal DNA and its transcripts

10

. Positive charge is a major factor in

localization and retention of proteins to the nucleolus. Mutagenesis studies of nucleolar
proteins, such as nucleolin, fibrillarin, and the viral HIV TAT, determined that clusters of
the positively charged amino acids arginine, and lysine serve as nucleolar localization
signals

11-12

. Furthermore, poly-arginines and -lysines, containing more than six amino

acids, rapidly penetrate cellular membranes and localize specifically to the nucleolar
region of cells 13-15.
TriplatinNC is a highly positively charged, (+8) non-covalent derivative of the
phase II clinical platinum drug, BBR3464

16

(Fig. A.1 A,B). The crystal and molecular

structure of TriplatinNC associated with a double-stranded B-DNA dodecamer 5′d(CGCGAATTCGCG)2 at 1.2 Å resolution (PDB:2DYW), shows formation of phosphate
clamps, involving two modes of DNA binding: "backbone-tracking", by following along
the phosphate backbone of one strand, or "groove-spanning", by crossing over the
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minor groove to interact with both strands

17

. The phosphate clamp motif is a discrete

third mode of DNA binding, distinct from intercalation or minor groove binding. These
interactions are mediated through hydrogen bonding, and are analogous to the "arginine
fork”, an important motif for protein-DNA interactions, where positively charged
guanidino groups of arginine, interact with negatively charged oxygens of DNA
phosphate 18-20, (Fig. A.1C). We have extended this analogy with the hypothesis that the
charged nature of TriplatinNC, like poly-arginines, may facilitate its localization to the
nucleolar compartment within cells.
In this report, we reveal remarkable differences in the cellular localization
pattern of TriplatinNC compared to cisplatin. The fluorophore-drug conjugate,
TriplatinNC-NBD, but not cisplatin-NBD, rapidly accumulates within the nucleolar region
of the cell. As an early event upon cellular treatment with TriplatinNC, there is a
resulting decrease in the production rate of 47S rRNA precursor transcripts. Further
studies detailed in this report set a timeline of the subsequent morphological,
antiproliferative, and apoptotic events.
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Figure A.1 Structures of (A) BBR3464 and (B) TriplatinNC. The noncovalent polynuclear compound,
TriplatinNC, is a direct structural analog of the Phase II drug BBR3464, where the labile chloride ion is
replaced by the amine group, NH2(CH2)6NH2. (C) Chemical similarity of "arginine-fork" (left), and
"phosphate-clamp" (right) interactions, http://pubs.rsc.org/en/Content/ArticlePDF/2010/CC/C0CC01254H
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Results and Discussion
TriplatinNC rapidly accumulates within the nucleolus. To determine differences in
the cellular localization pattern of TriplatinNC compared to Cisplatin, each compound
was labeled with the small fluorophore, 7-nitrobenzoxadiazole (NBD). The resulting
drug-NBD conjugates, Cisplatin-NBD and TriplatinNC-NBD (Fig. A.2A), retain charge
properties and inhibitory concentration (IC) values comparable to that of the parent
compounds (Fig. A.3). Confocal microscopy showed that TriplatinNC-NBD, but not
Cisplatin-NBD, rapidly accumulates to punctate regions of the nucleus in HCT116 colon
carcinoma and A2780 ovarian carcinoma cell lines (Figure A.2 B,C). In colocalization
studies, the distinct nuclear localization patterns of TriplatinNC overlaps the signal of the
commonly used nucleolar marker, Fibrillarin, a ribonucleoprotein methyltransferase
involved in the first steps of ribosomal RNA (rRNA) processing (Figure A.2D). Due to
this unique pattern of localization, and the charged nature of the drug, it was considered
that TriplatinNC was likely to interact with ribosomal DNA/RNA within the nucleolus.
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Figure A.2 Fluorescently-tagged TriplatinNC localizes to the nucleolus. (A.) Structures; Fluorophore
conjugates Cisplatin-NBD and TriplatinNC-NBD. (B.) Confocal Microscopy; The cellular distribution of
NBD-Cisplatin (green) in A2780 cells after 24hrs incubation in 10µM drug. (C.) NBD-TriplatinNC (green)
in A2780 and HCT116 cells after 2hrs incubation with 20µM drug, respectively. The DNA is subsequently
stained with DAPI (blue) as reference. (D.) Colocalization (orange) of NBD-TriplatinNC (green) with the
nucleolar marker, fibrillarin (red), in HCT116 cells after 4hrs incubation in 20µM drug. Anti-fibrillarin signal
was detected using a secondary antibody conjugated to Alexa-fluor 647.

156

Figure A.3 MTT Assay; A2780 or HCT116 cells were treated with the indicated concentration of drug for
72hrs. In each graph the drug-NBD derivative is denoted in dark gray and the parent compound in light
gray. (A.) A2780 cells treated with TriplatinNC-NBD and TriplatinNC. (B.) HCT116 cells treated with
TriplatinNC-NBD and TriplatinNC-NBD. (C.) A2780 cells treated with Cisplatin-NBD and Cisplatin. (D.)
HCT116 cells treated with Cisplatin-NBD and Cisplatin. Percent Inhibition is calculated as: 1-(N/N0),
where N=treated samples and N0= untreated control samples. Data are shown as mean ± s.d.
representative of at least 2 independent experiments.
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As an early event, TriplatinNC disrupts the rate of rRNA transcription. Initiation of
rDNA transcription requires assembly of a specific multiprotein complex that binds to the
rDNA promoter containing RNA Polymerase I (Pol I), and two Pol I specific transcription
factors, upstream binding protein (UBF), and the promoter selectivity factor complex,
SL1

21

. The binding specificity of Pol I at rDNA promoters is conferred by SL1

22

,

comprised of the transcription factor TBP (TATA-Box Binding Protein) and several
auxiliary TBP-associated factors 23-24. The ability of TriplatinNC to inhibit the interactions
of TBP with DNA was examined in vitro using the Electromobility Shift Assay (EMSA).
TriplatinNC was found to reduce TBP-DNA complex by 50% using between 0.63 and
1.25µM drug concentrations (Fig. A.4A), which is nearly 100-fold more effective than the
similar, less positively charged (+6) platinum agent, AH44 (Fig. A.5). This study
suggests the possibility that TriplatinNC may inhibit RNA transcription by displacing
DNA-binding proteins required for this process.
To determine whether TriplatinNC affects the rate of rRNA transcription in vivo,
HCT116 cells were treated with varying drug concentrations for 5.5hrs, and then
metabolically labeled according to the scheme depicted in Fig. A.4B. The 47S rRNA
precursor transcript is sequentially cleaved to yield the mature 28S, 18S, and 5.8S
rRNAs. As cells are pulsed with 32P-radiolabeled orthophosphate for 30 min. followed by
a 3h chase, the abundance of newly formed 47S precursors, 32S intermediate cleavage
products, and mature 28S and 18S rRNAs are sufficiently labeled for visualization by
autoradiography (6). It was evident that treatment of cells with TriplatinNC inhibits the
production rate of 47S rRNA precursor transcripts in a dose dependent manner (Figure
A.4B). It does not appear that TriplatinNC affects the rate of 47S rRNA processing, as
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the abundance of 32S, 28S, and 18S rRNAs decrease proportionally to that of the
precursor.
The transcriptional activity of rRNA genes has been shown to change in
accordance with the cell cycle

25

. rRNA transcription levels are highest in S and G 2

phases, nonexistent in mitosis, and rebounding in G1 26-27. Therefore, it was important to
consider whether the inhibitory effect of TriplatinNC on the rate of rRNA transcription
was direct, or if rRNA transcription levels were merely downregulated as an indirect
effect of changes within the cell cycle. The latter would be likely if there were an
increase in the population of cells in G1 (when rRNA levels are lower). For this purpose,
HCT116 cells treated with TriplatinNC were subjected to cell cycle analysis by flow
cytometry (Figure A.6 A, B). In cells treated with 20µM TriplatinNC ([IC90]) for 6hrs, there
were modest changes that occurred within the cell cycle. The population of cells in G 1
decreases slightly from 37% to 30% compared to untreated control cells, while the
population of cells within S+G2 increases slightly from 63% to 70%. These results imply
the disruption of rRNA transcription is an early event of cellular treatment with
TriplatinNC, and does not result from changes in the cell cycle.
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Figure A.4 TriplatinNC competitively inhibits TBP-DNA interaction and interferes with rRNA transcription.
32
(A.) EMSA; Lanes 3-9; 2nM P-labeled DNA incubated with 0.08, 0.16, 0.31, 0.63,1.25, 2.5, and 5uM
drug, respectively, followed by 100ng rTBP protein. Lane 2 is the ‘TBP/DNA complex’ positive control.
32
Lane 1 is the ‘free DNA’ control containing DNA only. (B.) P-Pulse/Chase Metabolic Labeling; Samples
were treated with or without drug according to the experimental outline. Lanes 1-8 were treated with 0.78,
1.6, 3.1, 6.3, 12.5, 25, 50, 100µM drug, or without drug in lanes 1 and 2. 1.5µgs total RNA was analyzed
for each sample. Ethidium Bromide (EtBr) staining of 28S rRNA was used as a loading control.
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+8

+6

32

Figure A.5 A. Structures of TriplatinNC and AH44 . B. EMSA; Lanes 3-9; 2nM P-labedled AdML DNA
oligo incubated with 0.032, 0.16, 0.8, 4, 20, 100, and 500uM drug, respectively, followed by 100ng rTBP
protein. Lane 2 is the ‘TBP-DNA complex’ positive control. Lane 1 is the ‘free DNA’ control, containing
DNA only.
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Figure A.6 TriplatinNC induces G1 cell cycle arrest. (A.) Flow Cytometry; Cell cycle analysis of HCT116
cells treated for 6, 24, and 48hrs with 20µM TriplatinNC (IC90) after RNase B treatment and staining with
propidium idodide. (B.) Modfit software analysis of histograms (excluding sub-G1). Data points are shown
as mean ± s.d. of 2 independent experiments with 2 replicates per sample (C.) Western Blot Analysis;
Time course analysis of p53, p21, and p27 protein expression after 20µM TriplatinNC for 3, 6, 12, and
24hrs. B-Actin is used as a loading control.
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At 24hrs, TriplatinNC induces a G1 cell cycle arrest. Anticancer therapeutics cause
28

proliferative arrest generally through induction of a classical signaling pathway

.

Central to this pathway is the stabilization of p53 protein by serine/threonine kinases,
followed by transactivation of the cyclin-dependent kinase (CDK) inhibitor, p21.
Increased protein levels of p21 inhibit CDK activities resulting in cell cycle arrest. This
pathway is induced by cisplatin, which has been shown to arrest cells at the G 2checkpoint as an attempt to repair DNA damage before cells enter mitosis

29-30

. In

agreement with these studies, HCT116 cells treated with 20µM cisplatin ([IC 90], Fig.
S1D) were shown to induce S-phase accumulation at 24hrs, and finally G2 arrest at
48hrs (Fig. A.7). Treatment of HCT116 cells with 20µM TriplatinNC, on the other hand,
induced an earlier arrest in G1 at 24hrs continuing to 48hrs. The increase in the number
of cells in G1 was mostly at the expense of the proportion of cells undergoing DNA
replication in S-phase, which decreased 52% at 24hrs and 77% at 48hrs compared to
the control. (Fig. A.6 A,B). As expected, there is a substantial stabilization of p53 protein
levels leading into the G1 arrest at 12 and 24 hrs after treatment with TriplatinNC (Fig.
A.6 C). However, p21 expression levels are not concomitantly upregulated in the
classical manner. Surprisingly, p21 protein expression levels decreased at 6 and 12 hrs,
and increase only to basal level at 24hrs. Furthermore, the protein expression levels of
p27, a similar CDK inhibitor with the potential to cause cell cycle arrest

31

, also

decreased. These data suggest that the G1-arrest induced by TriplatinNC may not
depend on classical signaling events. The fact that TriplatinNC induces G 1-arrest in the
HCT116 isogenic cell lines lacking either p53 or p21 (Fig. A.8), furthers this point. It is
tempting to speculate that TriplatinNC may disrupt the cell cycle at G1, because S-
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phase has the highest requirements for rRNA production

32

. The consideration that G1-

cyclin proteins may be synthesized in insufficient amounts to allow for the transition into
S-phase is a subject of continuing research.
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Figure A.7 Flow Cytometry; Cell cycle analysis of HCT116 cells treated for 0, 24, and 48hrs with 20uM
Cisplatin after RNase B treatment and staining with propidium idodide.
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Figure A.8 Flow Cytometry; Cell cycle analysis of HCT116, HCT116 p53-/-, and HCT116 p21-/- cells
treated for 0, 24, and 48hrs with 20uM TriplatinNC after RNase B treatment and staining with propidium
idodide.
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TriplatinNC causes rapid proliferative arrest and cell death independently of p53
status. In cells undergoing apoptosis, activated cysteine proteases, caspases-3, -6, -7,
result in cleavage of cytoskeletal proteins and fragmentation of nuclear DNA. These
events result in visible changes to the morphology of the cell including cell shrinkage,
chromatin condensation, cytosolic vacuolization, and membrane blebbing

33

. Changes

in physiology of HCT116 cells treated with 20µM TriplatinNC-NBD were visualized using
confocal microscopy after 2, 10, and 30hrs of treatment (Fig. A.9A). After 10hrs of
treatment, cells are much smaller in size and exhibit prolific cytosolic vacuolization. After
30hrs of treatment, blebbing and disintegration of the outer membrane is apparent.
Nearly all cancers harbor genetic defects that directly, or indirectly, inhibit
normal proapoptotic, or tumor suppressor functions of p53

28

. For this reason, we asked

whether the absence of p53 affects the ability of TriplatinNC to effectively induce
proliferative arrest and cell death. HCT116 p53+/+ and p53-/- cells were treated with
20µM cisplatin or TriplatinNC for 12, 24, 48, or 72hrs. Using the MTT assay, it was
determined that the ability of cisplatin to inhibit cell growth was significantly limited in the
absence of p53 (Fig. A.9B). However, the inhibitory effects of TriplatinNC on cell growth
was unaffected by the absence of p53 protein (Fig. A.9C). In support of these results,
we asked further whether the absence of p53 affects the ability of TriplatinNC to inhibit
colony-formation, or reproductive viability, using the clonogenic survival assay. HCT116
p53+/+ and HCT116 p53-/- cells were treated with 20µM TriplatinNC for 24, 48, and
72hrs (Fig. A.9C, Fig. A.10). The percentage of cells that failed to replicate was
determined to be between 63-75% after 24hr, 86-90% after 48hrs, and 85-99% after
72hrs. There was no significant difference in cells with or without p53.
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Figure A.9 TriplatinNC causes rapid proliferative arrest and cell death. (A.) Confocal Microscopy;
Morphological effects on HCT116 cells treated with 20µM TriplatinNC for 2, 10, and 30hrs include a
reduction in cell size, membrane blebbing, and cytosolic vacuolization (white arrows). (B.) MTT Assay;
Comparison of growth inhibition in HCT116 p53+/+ (lt gray) and p53-/- (dk gray) cells treated with 20uM
cisplatin or TriplatinNC. Percent Inhibition is calculated as: 1-(N/N0), where N=treated samples and N0=
untreated control samples. Data points are shown as mean ± s.d. of 2 independent experiments with 3
replicates per sample. **p<0.05, ***p<0.005 (C.) Clonogenic Survival Assay; Comparison of reproductive
viability in HCT116 p53+/+ cells and p53-/- cells treated with 20uM TriplatinNC for 24 and 48hrs. Plates
are representative of 4 independent experiments with 2 replicates per sample; mean ± s.d. of the
combined data is shown in Fig. S5.
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Figure A.10 Clonogenic Survival Assay; Comparison of colonies formed in HCT116 p53+/+ cells (black)
and HCT116 p53-/- cells (gray) treated with 20uM TriplatinNC. Percent Inhibition is calculated as: 1(N/N0), where N=treated samples and N0= untreated control samples. Data are shown as mean ± s.d.
representative of 4 independent experiments.
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After 48hrs, TriplatinNC induces a robust apoptotic signaling cascade. TriplatinNC
induces apoptosis in mast cells through activation of the mitochondrial-dependent
pathway initiator, procaspase-9, and the downstream effector, procaspase-3

34

. In

extension of these studies, it was determined whether TriplatinNC induced
accumulation of the activated forms of procaspase-9 and procaspase-3 in p53(+/+) as
compared to p53(-/-) HCT116 isogenic colon carcinoma cell lines. Both cells lines show
a time-dependent increase in active caspase-9 and caspase-3 after treatment with
20µM TriplatinNC (Fig. A.11A). At 30 or 55hrs after treatment in p53-/- cells, there is
less accumulation of active caspase-9 compared to the untreated control than in p53+/+
cells. However, the abundance of active caspase-3 appears to be unaffected by the
absence of p53. Therefore, it was asked whether caspase-3 may be activated also by
the initiator of the mitochondrial-independent pathway of apoptosis, caspase-8.
Caspase-8,

has

the

ability

to

activate

procaspase-3

through

both

mitochondrial-dependent and -independent apoptotic pathways. In the mitochondriadependent pathway, caspase-8 cleaves BID to tBID, which translocates to the
mitochondria and causes damage by culminating an efflux of death promoting proteins
such as cytochrome-C. These events, in turn, lead to activation of procaspase-9,
followed by procaspase-3. In the mitochondrial-independent pathway, caspase-8
instead directly activates procaspase-3, and downstream substrates such as Parp-1,
eventually leading to cell death

35

. In HCT116 cells treated with 20µM cisplatin for

48hrs, it was determined that the abundance of active caspase-8 (p18) and downstream
target, Parp-1, is severely reduced in cells lacking p53 as compared to the wild-type
control (Fig A.11B). However, treatment with 20µM TriplatinNC for 48hrs induced similar
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levels of active caspase-8 and Parp-1 in p53+/+ and p53-/- cells (Fig. A.11C).
Furthermore, TriplatinNC does not induce the cleavage of BID into tBID (Fig. A.12),
therefore, the mitochondrial-dependent and independent pathways are likely activated
independent of each other 36.
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Figure A.11 TriplatinNC induces activation of caspases independent of p53. (A.) Western Blot Analysis;
Timecourse analysis of cleaved caspase-9 and -3 protein in HCT116 p53+/+ and p53-/- cells treated with
20µM TriplatinNC for 5, 15, 30, and 55hrs. (B., C.) Comparison of cleaved caspase-8 and Parp-1 protein
in HCT116 p53+/+ and p53-/- cells treated with 20µM Cisplatin or TriplatinNC at 48hrs. B-Actin was used
as a loading control.
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Figure A.12 Western Blot; Comparison of BID (p22) and the active form, tBID (p15) proteins in HCT116
p53 treated with 20uM Cisplatin or TriplatinNC at 48hrs. B-Actin was used as a loading control.
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Summary. This study highlights remarkable features and cellular consequences of the
noncovalent polynuclear platinum agent, TriplatinNC. Within hours, TriplatinNC
accumulates within cells and localizes specifically to the nucleolus. The immediate
decrease in rate of rRNA transcription, followed by G1 arrest, is a likely result of unique
'phosphate clamp' DNA binding motif employed by TriplatinNC, which competitively
inhibits TBP-DNA interactions. TriplatinNC activates the apoptotic program through
mitochondrial-dependent and -independent caspase pathways. TriplatinNC induces
morphological changes in cells consistent with the process apoptosis, including
shrinkage in cell size, cytosolic vacuolization, and membrane blebbing. Furthermore,
TriplatinNC effectively induces proliferative arrest and cell death independent of p53.
The activity of TriplatinNC in human cancer cell lines extends to antitumor activity
observed in vivo using the 2008 human tumor xenograft mouse model. (Fig. A.13 and
Table A.1). The results presented here support a basis for selective targeting of rRNA
processes as a strategy for p53-independent induction of apoptosis in cancer cells and
pave the way for an entirely new class of platinum-based anticancer therapeutics.
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Figure A.13 2008 ovarian tumor human xenograft model: Animals were treated on days 0, 4, 8 with either
25mg/kg TriplatinNC by ip injection, saline (0.1ml/10g body weight), or on days 0, 7, 14 with 4mg/kg
cisplatin by ip injection.
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Table A.1 Effect of cisplatin and TriplatinNC against the 2008 ovarian tumor xenograft mouse model.
Drug efficacy was assessed by measuring the TGI (tumor growth inhibition) on day 10, indicating %
decrease in tumor volume in drug treated animals vs. control, GDI (tumor growth delay index) indicating
the number of days the tumor takes to reach 3 (a) or 4 (b) times its starting size, and AGD (absolute
growth delay), calculated as median time in days to reach 3 times starting tumor volume.
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Materials and Methods
Drug Synthesis. Cisplatin was synthesized as previously described; [Wong, E.S.Y.;
Giandomenico, C.M., Patent No. 09678595]. TriplatinNC and AH44 were synthesized
as described previously (16). The synthesis of TriplatinNC-NBD and Cisplatin-NBD are
described in the Supplemental Methods section.
Cell Culture and Drug Treatments. HCT116, HCT116 p53-/-, and A2780 cell lines
were cultured in RPMI 1640 (Invitrogen), supplemented with 10% calf serum (Atlanta
Biologicals) and 1% penicillin/streptomycin (Invitrogen). Cells were maintained in
logarithmic growth as a monolayer in T75 culture flasks at 37°C in a humidified
atmosphere containing 5% CO2. For drug treatment studies, unless otherwise noted,
the molar drug:cell ratio was kept constant by seeding 5x104 cells/mL media throughout.
Confocal Fluorescence Microscopy. 5x104 cells were seeded on chamber slides
(Lab-Tek II) in media. 24hrs after seeding, cells were treated with TripaltinNC-NBD or
Cisplatin-NBD at the indicated times and concentrations. After removing the media,
cells are washed with PBS and mounted as described below. For Immunofluorescence
of fibrillarin, cells were permeabilized with 0.5% Triton-X in PBS for 10 min. and blocked
in PBS/Casein for 1hr at room temperature. 1:200 dilution of primary antibody, antifibrillarin (cell signaling, clone C13C3) was added overnight at 4°C, then a 1:500 dilution
of secondary antibody anti-rabbit IgG Alexa 647 conjugate (cell signaling) for 3 hrs at
room temperature. The antibodies are then fixed with 3% paraformaldehyde for 15 min.
at room temperature. All slides were mounted in VectaShield with DAPI (Vector Labs)
and viewed using a Zeiss LSM 510 confocal microscope.
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Flow Cytometry. HCT116 cells were drug treated for 6, 24, and 48hr. 1x10 6 cells were
suspended in 1ml of propidium

iodide solution (3.8mM sodium citrate; 0.05mg/ml

propidium iodide; 0.1% Triton X-100) with added RNAse B (7000units/ml) and kept in
the dark at 4°C. Cells were analyzed by flow cytometry on a CoulterElite XL-MCL
(Beckman Coulter). Twenty thousand events were acquired and analyzed using Modfit
software.
Metabolic Labeling and rRNA analysis. 2x105 HCT116 cells were grown in 6-well
plates in 4ml RPMI/10% FBS media for 24hr. Cells were drug treated for 5h. For
phosphate depletion, complete media was replaced with phosphate-free DMEM/10%
dialyzed FBS containing drug and incubated for 30 min. before the addition of 15µCi/ml
32

P-orthophosphate (Perkin Elmer) and further 30 min. incubation. Medium was again

changed to RPMI/10% FBS drug-containing medium for 3hr and total RNA was isolated
using RNeasy (Qiagen). RNA concentration was determined using a Nanodrop. 1.5ug
of total RNA was separated on a 1% agarose-formaldehyde gel. After electrophoresis,
28S rRNA quantities were visualized with Ethidium Bromide as a loading control. Gels
were placed on Whatman paper and dried for 2hr at 80°C under vacuum suction. Dried
agarose gels were exposed to x-ray film.
Electromobility

Shift

Assay.

2nM

end-labeled

dsDNA

(24mer

5’-

GAAGGGGGGCTCTAAAAGGGGGTG-3’ containing the AdML TATA box.) was
incubated for 15 min. at 30°C with or without drug in a final volume of 10µs reaction
buffer (20mM Hepes-KOH, pH7.9, 25mMKCl, 10% glycerol, 0.025% NP-40, 100 µg/mL
BSA, 0.5mM DTT, 0.1mM EDTA, and 2mM MGCl2). Where indicated, 100ng rTBP
(Santa Cruz) was added to the reactions and was further incubated for 30 min. The
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reactions were separated by electrophoresis in a 6% native polyacrylamide gel in 0.5x
TBE buffer (45mM Tris-HCl, 44mM boric acid, and 2mM MgCl2). The gel was dried and
exposed to x-ray film.
Growth Inhibition Assay. Cells were seeded in a 96-well plate at 5 x103 cells/well in
100µl media and allowed 24hrs to attach. Cells were then drug treated for a period of
72hrs. After removal of drug, the cells were treated with 0.5mg/mL MTT reagent [(3,4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma] in media for 3hrs at 37°C.
The MTT reagent was removed and 100µl of DMSO was added to each well. The plate
was then incubated on a shaker at room temperature in the dark. The
spectrophotometric reading was taken at 570nm using a microplate reader.
Clonogenic Survival Assay: 2x104 HCT116 +/+ and HCT116-/- cells were seeded in
3ml of medium in a 6-well plate. After 24hrs of incubation, cells were drug treated for a
24hr period. 250 or 2500 cells were seeded into 10cm dishes and allowed to grow for
10-14 days to form colonies. These were then fixed by methanol and stained by 0.1%
crystal violet. Colonies consisting of more than 50 cells were counted. Plating efficiency
and surviving fraction were determined for each drug.
Immunoblot Analysis: Primary antibodies used were p53 (cell signaling, # 9282), p21
(Santa Cruz, clone F-5), p27 (cell signaling, clone SX53G8.5), total caspase-3 (cellsignaling, 9662), total caspase-8 (cell signaling, clone IC12), cleaved caspase-9 (cell
signaling, #9501), cleaved Parp (cell signaling, # 9541), and B-Actin (Abcam, ab8226).
After drug treatments, both floating and adherent cells were harvested. Cells were
washed with ice-cold PBS, repelleted, and, resuspended in SDS lysis buffer (62.5mM
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Tris-HCl, pH 7.5, 5% glycerol, 4% SDS, 4% complete protease inhibitor (Roche), 5%
BME). After homogenization, proteins were resolved on 7.5-15% polyacrylamide gels,
transferred to PVDF membrane, and blocked in 5% non-fat milk at room temperature for
1 hr. The membranes were probed with primary antibodies overnight, followed by
secondary anti-rabbit, or anti-mouse antibodies conjugated to horseradish peroxidase
(Cell Signaling, Thermo Scientific). Chemiluminescent protein bands were visualized on
X-ray film.
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Abstract
The interactions of polynuclear platinum complexes with human serum albumin
were studied. The compounds examined were the ―non-covalent‖ analogs of the
trinuclear BBR3464 as well as the dinuclear spermidine-bridged compounds differing in
only the presence or absence of a central -NH2-+ (BBR3571 and analogs). Thus,
closely-related compounds could be compared. Evidence for pre-association,
presumably

through

electrostatic

and

hydrogen-bonding,

was

obtained

from

fluorescence and circular dichroism spectroscopy and Electrospray Ionization Mass
Spectrometry (ESI-MS). In the case of those compounds containing Pt-Cl bonds, further
reaction took place presumably through displacement by sulfur nucleophiles. The
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implications for protein pre-association and plasma stability of polynuclear platinum
compounds are discussed.

Introduction
Polynuclear platinum complexes (PPCs) containing two or three platinum units
linked by alkanediamine or polyamine chains comprise a structurally distinct class of
anticancer active platinum compounds, Figure B.1.1 A distinct feature of these
compounds is the presence of a central moiety capable of pre-association or ―noncovalent‖ (hydrogen-bonding and electrostatic) interactions with biomolecular targets.
The three global pharmacological factors controlling platinum drug cytotoxicity and
antitumor activity are cellular uptake, the frequency and structure of DNA adducts, and
the extent of metabolizing interactions. The presence of the central unit (platinumtetraam(m)ine coordination sphere or the polyamine nitrogen) in polynuclear platinum
compounds allows for modulation of these pharmacological factors and may affect drug
efficacy.
The role of pre-association in dictating the final products of reaction of PPCs with
biomolecules has been assisted greatly in the trinuclear case by the synthesis and
evaluation of ―non-covalent‖ analogs where the Pt-Cl bonds are displaced by a
substitution-inert NH3 or a ―dangling‖ amine H2N(CH2)6NH3+ (structures Ia or Ib, Figure
B.1).2-3 Similar strategies can be used for polyamine-bridged dinuclear compounds.
Further, the synthetic strategies involved in producing linear polyamine-bridged species
automatically give rise to a precursor where the central nitrogen is blocked, usually by a
carbamate such as t-butyl (Boc).4 This pair of compounds then only differs in charge
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and the presence or absence of a central protonated nitrogen atom. The central
nitrogen atom is susceptible to selective attack using, for example, various carbamate
or amide blocking groups (structures II, IIa, and IIb, Figure B.1).5
The rate of DNA platination as well as the amount of long-range interstrand
crosslinks (where the sites of platination are separated by up to 4 intervening base
pairs) is affected by charge and hydrogen-bonding capacity of the linker.6 For 1,4
interstrand crosslink directional isomers (3′ → 3′ and 5′ → 5′ crosslinks) are formed. The
relative proportion of these adducts is dependent on hydrogen-bonding and charge
effects within the linker.7-8 The X-ray crystal structure of a duplex DNA co-crystallized
with Ib demonstrated a new mode of DNA ligand binding—a phosphate clamp—where
hydrogen-bonding interactions with the phosphate backbone may be arranged in a
modular manner.9
Intracellular platinum accumulation and cytotoxicity are also affected by charge.
In this case, a perhaps counter-intuitive observation is that cell uptake actually
increases with charge.3,10-11 Interestingly, cellular uptake of the spermidine-bridged
dinuclear compound II is greater than that of the blocked derivative IIa. 11 In these cases
enhanced cytotoxicity is always correlated with greater cellular uptake. 11-12 In
mechanistic studies with phospholipids, a ―non-covalent‖ interaction of Ia was also
observed, suggesting one possible mechanism for membrane transport of these highly
charged species.13
In this contribution we examine the reactions of polynuclear platinum compounds
with human serum albumin (HSA) and show for the first time the presence of a preassociated or ―non-covalent‖ interaction of a platinum drug on the protein. Reactions in
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plasma, and especially with HSA, are generally considered responsible for the
metabolic deactivation of platinum-based drugs. Understanding the molecular details of
such interactions may allow for strategies to manipulate their extent with consequent
effects on cellular uptake and even therapeutic index.
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Figure B.1 Structures of pairs of trinuclear (BBR3464 I, Ia, Ib) and dinuclear (BBR3571 II, IIa, IIb) studied
for pre-association effects on human serum albumin (HSA).
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Results and Discussion
The effects of charge on polynuclear platinum complex binding to human serum
albumin (HSA) were examined with two sets of compounds. Firstly, the trinuclear
BBR3464 I was compared with its non-covalent analog Ia and secondly, the effect of
blocking groups in the central nitrogen of the spermidine-linked dinuclear species was
evaluated (II, IIa, IIb). See Figure B.1 for structures. Global changes in protein
conformation can be assessed by circular dichroism (CD) and fluorescence
spectroscopy.14-15 The CD spectrum of HSA exhibits two negative bands in the
ultraviolet region at 208 and 220 nm characteristic of an α-helical structure of the
protein. The fluorescence from excitation of HSA at 298 nm reflects changes in the
microenvironment of the tryptophan 214 residue, serving as a tool to obtain information
about conformational changes of the protein.14 A decrease in fluorescence of the lone
tryptophan of HSA is interpreted as a conformational change making the amino acid
more accessible to water quenching.

Trinuclear platinum complexes
Fluorescence spectroscopy
At t = 0 the relative decrease in fluorescence is concentration dependent for both
BBR3464 and the ―non-covalent‖ analog Ia. Over time the relative decrease for
BBR3464 is significantly greater than at t = 0 for all concentrations whereas for the
―non-covalent‖ analog there is little or no further perturbation of the system, Figure B.2.
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Figure B.2 Changes in fluorescence of HSA treated with trinuclear platinum compounds. Note no
significant change for the “non-covalent’ analog over time.
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CD Spectroscopy
The CD spectrum of HSA incubated with PPCs is time and concentration-dependent.
Immediately upon mixing 1:1 ratios of Pt complex:HSA the ellipticity of the negative
band at 208 nm is increased (to more negative values) and the spectra do not change
over a 24 h time period, Figure B.3. At t = 0 the spectra for BBR3464 (3) and Ia (4) are
superimposable. In contrast when 10:1 ratios are used, the spectrum corresponding to
the BBR3464 reaction (1) changes and the ellipticity is reduced (less negative values).
In fact the spectra become similar to those observed for 20-fold excesses of either cDDP or its trans isomer upon extensive incubation with HSA and diminution of the αhelical content of the protein.15 Likewise, the binding of the ruthenium antitumor
drug trans-[RuCl4(Im)2]- (Im = imidazole) induces considerable concentration-dependent
change (up to 15%) of the secondary structure upon binding. 16 These results and others
17-18

are therefore consistent for the concept of bond-formation at the higher

concentration. The most likely binding sites in all cases remain the sulfur amino acids
and the CD results in general are consistent structural transitions of HSA being
dependent on the state of the cysteine Cys34.19 In contrast to all these cited cases
where bond formation is expected to occur, there is little or no change for the ―noncovalent‖ analog (5) at the higher ratio, Figure B.3. Thus, the pre-association is also
indicated to actually increase the order of the secondary structure with an enhancement
of α-helical content.
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Figure B.3 CD spectra of HSA incubated with compounds I or Ia at different ratios; drug:HSA, 1:1 and
10:1 after 24 h. Note no significant change for the “non-covalent” analog after 24 h. (*) Spectra of I (3)
and Ia (4) overlap from 195-250 nm.
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ESI-Mass spectrometry
It is reasonable to conclude from both the fluorescence and CD data that the spectral
changes induced by Ia, which are invariant over time, represent a ―pre-association‖ or
non-covalent binding to the protein. At t = 0 the binding of BBR3464 also represents a
significant contribution from the non-covalent ―pre-association‖ and that further changes
are due to bond formation. To confirm the presence of this interaction, the compound Ia
was incubated with rHSA and the mixture examined by ESI-mass spectrometry, Figure
B.4. It is observed in the mass spectrum that a noncovalent interaction between the
polynuclear platinum compound Ia and rHSA takes place after a very short incubation
period. There is a 1015 Da shift in the deconvoluted spectrum (Figure B.4B) obtained
after incubation reveals that rHSA which corresponds to a 1:1 complex Ia with rHSA
with the presence of one of NO3- counter ion from the complex. Mass spectrometry has
also been used to directly observe c-DDP binding
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and also Cys34 binding to gold of

gold-based antiarthritic drugs.21 In the present case initial studies with BBR3464 caused
precipitation and no clean spectra were obtained—further studies are in progress.
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Figure B.4 (A) Nano-ESI-MS of rHSA incubated with Ia. rHSA-ligand bound peaks are designated with
(*). (B) Deconvoluted mass spectrum showing a mass shift of 1015 Da, corresponding to the addition of
Ia + one NO3 .
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Dinuclear spermidine-linked compounds
Designed synthesis of polyamine backbones gives a series of exceptionally
potent compounds which mimic successfully the biological activity of BBR3464.4,12,22
The critical feature in the biological activity is linked to the presence of a central charged
-NH2-+ on the polyamine linker. The role of pre-association in dinuclear polyaminelinked compounds can be examined by comparing the reactions of the charged species
and its uncharged or blocked analog. Interestingly, the relative decrease in fluorescence
at 1:1 ratios was significantly less for the blocked derivatives. In this case, however the
presence of Pt-Cl bonds does mean that over time platinum-protein bond formation may
take place and this is reflected in an enhanced fluorescence decrease over time for all
compounds, Figure B.5. It is of interest to note however, that this decrease is not as
great as that seen for BBR3464. In agreement with the changes in fluorescence the CD
spectrum of HSA bound to BBR3571 after 48 h appears similar to that of BBR3464 at
high Pt:HSA (10:1) ratios (data not shown).
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Figure B.5 Changes in fluorescence of HSA treated with dinuclear platinum compounds.
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It is generally considered that chemical changes of platinum compounds on HSA
lead to deactivation.14,23 A study of a series of mononuclear and dinuclear derivatives
of meso-1,2-bis(4-fluorophenyl)ethylenediamine showed strong binding to HSA by
hydrophobic and electrostatic interactions, leading to reduced cellular uptake and
decreased potency.24 A pharmacological principle is that free (non-protein-bound) drug
is active, being able to diffuse readily to tissue. Therefore to evaluate and quantitate the
binding of PPCs to HSA, BBR3464 and Ia were incubated and the ultrafilterable protein
unbound fraction was quantified for selected time points, Figure B.6. Analysis by ICPOES shows a decrease in Pt content immediately upon mixing, t = 0, for both BBR3464
and Ia. This initial decrease in Pt content represents the non-covalent, ―pre-association‖
of the Pt complex with protein. The Pt content corresponding to BBR3464 decreases
with time, representing a displacement of the Pt-Cl bond and a formation of the
covalently bound Pt-protein species (where covalent is used to indicate Pt-amino acid
residue formation independent of strict contributions of covalent or coordinate bonding).
In contrast, ICP-OES analysis of Ia shows a constant Pt concentration from t = 0
through t = 24 h. Due to the presence of the substitution-inert -NH3 group, the initial preassociation is not followed by a covalent Pt-protein interaction. Similar behavior was
observed for Ib.
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Figure B.6 ICP-OES analysis of Pt content in ultrafiltrate of BBR3464 and Ia after incubation with HSA for
selected time points.
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Conclusions
The results show that the initial reaction of human serum albumin with trinuclear
platinum compounds is one of ―pre-association‖, similar to that observed for DNA and
phospholipids. The mass spectral confirmation is the first, to our knowledge shown for
platinum antitumor agents. The strength of binding is apparently stronger than that seen
for free spermine, spermidine or the cation [Co(NH3)]63+, where the CD changes upon
incubation were minimal compared to free HSA.25 The ―pre-association‖ observed for I
and Ia can be also observed for complexes II—where the presence of a blocking group
diminished the initial interaction as a cause of diminished charge and hydrogen-bonding
capacity of the central nitrogen. The proposed binding sites for platinum on HSA are the
Cys-34 and Met-298, located on the exterior of the protein in sub-domains I and II.1415,20,23

There are a number of interesting points to consider based on this
understanding. Human serum albumin is a versatile transport protein and receptor for a
variety of ligands and drugs. The primary function of HSA is the transport of fatty acids
but since it carries a negative 17 charge, it is also responsible for shuttling a wide
variety of metal ions, steroids, and a variety of pharmaceuticals. The crystal structure of
human serum albumin has allowed the identification of the principal ligand-binding
domains located in the hydrophobic cavities of sub-domains IIA and IIIA.26-27

In

principle the receptor sites for the highly-charged cations as represented by PPCs in
this study should be distinct from the Cys and Met covalently-binding sites. It may,
therefore, eventually be possible to plot the migration of the pre-associated form to the
platinated species. Secondly, the identified metabolic products of BBR3464 can be
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mimicked by reactions with small sulfur nucleophiles such as glutathione and
methionine.28-30 HSA constitutes roughly 60% of the mass of plasma proteins with a
concentration of ∼40 mg mL-1. It is highly likely therefore that HSA binding could
contribute to these metabolic deactivation reactions, as suggested also for some similar
dinuclear complexes.24 Finally, as a corollary, the results for Ia and Ib suggest that
these non-covalent compounds may ―by-pass‖ the deactivation associated with Pt-S
bond formation. This is especially important for Ib. This 8+ compound is taken up into
cells in a significantly greater concentration than either BBR3464 or Ia, and as a result
has demonstrated in vitro cytotoxicity equivalent to cisplatin. The ―non-covalent‖
compounds have shown a new mode of DNA binding distinct from intercalation and
minor-groove binding. The interaction, but not deactivation, on HSA suggests a new and
promising profile for a polynuclear platinum drug.

Experimental
Sample preparation
All platinum compounds were as prepared previously.2-5 Human serum albumin
(essentially fatty acid free) was purchased from Aldrich/Sigma. Recombinant human
serum albumin (rHSA) (Recombumin®), expressed in Saccharomyces cerevisiae, was
a generous gift from Delta Biotechnology Limited (Nottingham, UK). A stock solution of
phosphate buffered saline ([phosphate] = 150 mM, pH 7.35 at 37 °C, [NaCl] = 120 mM,
[KCl] = 2.7 mM)) (PBS) was prepared and used for all reaction solutions in order to
mimic physiological conditions. HSA was incubated with platinum reactions at a
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constant temperature of 37.5 °C prior to obtaining spectroscopic data, which was
acquired at room temperature.

UV-Visible spectroscopy (UV-Vis)
Absorption spectra were recorded on a JASCO V-550 UV-Vis spectrophotometer. HSA
concentration was determined from the absorption spectrum, taking the absorbance of a
1 mg mL-1 solution at 280 nm (λmax Trp-214) as 0.55.15

Circular dichroism (CD)
CD spectra were measured on a Jasco J-600 UV dichrometer using a 0.3 mm (openended side plate) quartz crystal cuvette. A bulk solution of HSA was prepared at a 38.5
mg mL-1 (1.12 × 10-4 M) concentration. HSA/Pt reactions were conducted at a 1:1 and
10:1 (drug:HSA) stoichiometry. Spectral measurements were recorded at t = 0 and
selected time intervals.

Fluorescence spectroscopy
Fluorescence measurements were conducted on a Cary Eclipse Fluorimeter with the
excitation and emission wavelengths set at 279 and 310 nm, respectively, with a scan
rate 120 of nm min-1. PMT voltage was set manually to 409 V. The reactions of platinum
compounds were studied at various reactant ratios, predominantly 1:1 and 10:1
(Pt:HSA). An initial concentration for a 10:1 reaction was prepared for each drug. Each
solution was then diluted to the specific concentration needed for the desired ratio. Each
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reactant was incubated in a shaker bath at 37.5 °C for 45 min prior to reacting. Separate
measurements were taken at t = 0 and appropriate time intervals.

Electrospray Ionisation Mass Spectrometry (ESI-MS)
Experiments were conducted on a Waters/Micromass (Manchester, UK) QTOF-2 mass
spectrometer. A custom built nano-ESI source was used with a capillary voltage of 2.1
kV and a cone voltage of 36 V. Source block temperature was maintained at 150 °C.
ESI-solutions consisted of methanol:water (50:50 v/v) with 0.1% formic acid. The
solutions were infused at 0.5 μL min-1 using a Harvard Apparatus Model 22 syringe
pump (Harvard Apparatus, Holliston, MA). Data acquisition and processing were carried
out using the MassLynx 4.0 software. Stock solution of AH 44 was 500 μM in water and
made fresh before ESI-MS experiments. Aliquots from the stock solution of rHSA, 139
μM, were mixed with the polynuclear platinum compound Ia in a 1:2 molar ratio in water
and incubated at 37 °C, for 15 min. Incubated samples were mixed in the ESI solution to
give a final rHSA concentration of approximately 40 μM.

Inductively Coupled Plasma-Optical Emission Spectroscopy (ICP-OES)
1.8 mM solutions of each complex were prepared in phosphate buffer and added to 0.6
mM HSA such that the final concentration of complex was 0.9 mM; (3:1; drug:HSA) The
mixture was reacted at 37 °C and 100 μL aliquots were removed at t= 0, 0.5, 2, 6, and
24 h. Aliquots were then centrifuged through a Microcon YM-10 10 000 kDa membrane
filter at 14 000 g for 30 min to isolate ultrafiltrate. The centrifuge cup was upturned in a
second eppendorf and then centrifuged at 1000 g for 3 min to isolate the protein-bound
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fraction. Samples were digested following published methods. Pt content was recorded
at 214 nm and 265 nm, at each time point, using a Varian ICP-OES. Data are reported
as percentage of Pt in control vs. Pt per time point.
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